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ABBREVIATIONS 
 
APC: antigen presenting cell 
ARG: arginase 
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BAT-3: HLA-B-associated transcript 3 
B7-H: B7-homolog 
BM: bone marrow 
BM-MDSC: BM-derived MDSC 
BSA: bovine serum albumin 
BTLA: band T-cell lymphocyte attenuator 
CCL2: chemokine (C-C motif) ligand 2 
CDDO-Me: Methyl 2-cyano-3,12-dioxooleana-1,9(11)dien-28-oate, Bardoxolone 
methyl  
CD40L: CD40 ligand 
C/EBP-β: CCAAT-enhancer binding protein-β 
CIP: cancer immunotherapy immunoguiding program 
COX-2: cyclooxygenase-2 
CTL: cytotoxic T lymphocyte 
CTLA-4: cytotoxic T-lymphocyte antigen 4 
CXCL12: chemokine (C-X-C motif) ligand 12 
CXCR4: chemokine (C-X-C motif) receptor 4 
DC: dendritic cell 
ECM: extracellular matrix 
EDTA: ethylenediaminetetraacetic acid 
EGF: epidermal growth factor 
EGFR: epidermal growth factor receptor 
Egr2: early growth response gene 2 
ELISA: Enzyme-Linked Immunosorbent Assay 
ERK: extracellular signal-regulated kinase 
FBS: fetal bovine serum 
FcR: Fc receptor 
FLT3L: FMS-like tyrosine kinase 3 ligand 
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INF-γ: interferon-γ 
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LPS: lipopolysaccharide 
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PBMC: peripheral blood mononuclear cell 
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PDGFR: platelet-derived growth factor receptor 
PDE-5: phosphodiesterase type 5 
PD-1: programmed death-1 
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PGE2: prostaglandin E2 
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PKC: protein kinase C 
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ABSTRACT 
 
One of the mechanisms used by cancer to evade the immune response is the 
expansion of myeloid-derived suppressor cells (MDSCs), a population of 
immature myeloid cells able to inhibit immune responses in cancer patients and 
experimental animals with neoplasia. The role of MDSCs in promoting tumor 
growth and metastasis has gained importance over the years, highlighting the need 
to find specific target of intervention that could be used in the treatment of cancer 
patients.    
 
The aim of the present work was to analyze the signaling pathways active in 
MDSCs, using an in vitro model of MDSC generation developed by our group. 
Our previous studies revealed that the phenotype and suppressive ability of 
MDSCs were influenced by the presence of activated T cells, thus suggesting the 
existence of an interplay between the two populations. We therefore focused our 
attention on soluble molecules and surface markers mediating the interaction.  
 
We demonstrated that IL-10 release is increased in the culture between MDSCs 
and activated T cells and that this cytokine leads to the activation of STAT3 both 
in myeloid and lymphoid cells. One of the targets of STAT3 is B7-H1, a molecule 
that can deliver an inhibitory signal to T cell, interacting with its receptor PD-1.  
We therefore analyzed the expression of B7-H1 on MDSCs and we found that it is 
up-regulated in the presence of activated T cells through a STAT3-dependent 
signaling. By analyzing the fate of suppressed T cells, we observed that they 
express at higher level two markers of T cell exhaustion, PD-1 and LAG-3. LAG-
3 is a negative co-stimulatory receptor on T lymphocytes and the natural ligand of 
HLA class II, whose expression we found up-regulated in MDSCs after culture 
with activated T cells. These results thus suggest that the interplay between 
MDSCs and activated T cells could be mediated by the couples of receptor/ligand 
PD-1/B7-H1 and LAG-3/HLA class II, leading to T cell exhaustion.  
 8
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RIASSUNTO 
 
Uno dei meccanismi utilizzati dalle cellule tumorali per evadere la risposta del 
sistema immunitario è costituito dall’espansione delle cellule soppressorie di 
derivazione mieloide (MDSC), una popolazione di cellule mieloidi immature 
capaci di inibire le risposte immunitarie nei pazienti con tumore e in modelli 
murini con neoplasie. Il ruolo delle MDSC nel promuovere la crescita tumorale e 
la metastatizzazione ha acquisito sempre maggiore importanza negli ultimi anni, 
evidenziando la necessità di trovare specifiche vie di segnalazione attive in queste 
cellule che possano diventare bersaglio di interventi terapeutici mirati nel 
trattamento dei pazienti con tumore. 
 
Lo scopo di questo lavoro è stato quello di analizzare le vie di segnalazione attive 
nelle MDSC, utilizzando un modello sviluppato dal nostro gruppo per la 
generazione in vitro delle MDSC umane. I nostri studi precedenti hanno rivelato 
che il fenotipo e la capacità soppressoria delle MDSC sono fortemente influenzati 
dalla presenza dei linfociti T attivati, suggerendo l’esistenza di un’interazione tra 
le due popolazioni. Abbiamo quindi focalizzato la nostra attenzione su molecole 
solubili e marcatori di superficie che potrebbero essere coinvolti nell’interazione 
tra MDSC e cellule T attivate. 
 
Abbiamo dimostrato che il rilascio di IL-10 è aumentato nelle colture tra MDSC e 
cellule T attivate e che questa citochina porta all’attivazione di STAT3 sia nelle 
cellule mieloidi che in quelle linfoidi. Uno dei bersagli di STAT3 è B7-H1, una 
molecola che può fornire un segnale inibitorio alla cellula T, interagendo con il 
suo recettore PD-1. Abbiamo pertanto analizzato l’espressione di B7-H1 sulle 
MDSC e abbiamo notato che essa è aumentata in presenza delle cellule T attivate, 
mediante una via di segnalazione dipendente dall’attivazione di STAT3. 
Analizzando il destino dei linfociti T soppressi, abbiamo osservato che essi 
esprimono ad alto livello due marcatori di “exhaustion” delle cellule T, che sono 
PD-1 e LAG-3. E’ noto che LAG-3 è un recettore co-stimolatorio negativo sui 
linfociti T ed è il ligando naturale di molecole HLA di classe II, che sono 
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significativamente aumentate nelle MDSC dopo coltura con le cellule T attivate. 
Questi risultati pertanto suggeriscono che l’interazione tra le MDSC e le cellule T 
attivate potrebbe essere mediata dalle coppie di recettore/ligando PD-1/B7-H1 e 
LAG-3/HLA di classe II, portando ad “exhaustion” delle cellule T.  
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INTRODUCTION 
  
1.1 From immuno-surveillance to the theory of cancer 
immunoediting 
The immunosurveillance theory, that was formally enunciated in 1957 by Burnet 
and Thomas, states that immune system can eliminate malignant cells before they 
develop into detectable tumors by recognizing and inactivating them through the 
existence of tumor antigens, molecules present on neoplastic cells able to elicit a 
protective immune response 1-3. However, these data were criticized by part of the 
scientific community, as studies carried out subsequently on immunodeficient 
mice (nude mice) showed no higher incidence of tumor development, as 
compared to immunocompetent mice 4,5. However, now it has to be acknowledged 
that there were several limitations in the experimental model, that could not be 
appreciated at that time. In fact, the nude mouse still possesses α/β T cells and NK 
cells that could provide a reduced but significant cancer immunosurveillance 
ability. Only in the last 20 years, with the development of knock-out mice and 
transgenic technology and the possibility to produce highly specific monoclonal 
antibodies, the cancer immunosurveillance hypothesis was tested in molecularly 
defined immunodeficiency models and provided strong and convincing data. 
Further experiments revealed that the immune system exerts both host-protecting 
and tumor-sculpting effects on developing tumors. Therefore, the initial theory of 
cancer immunosurveillance was no more appropriate to describe the interaction 
between tumor and immune system, so Robert Schreiber and collaborators 
proposed to use the broader term “Cancer immunoediting” to describe more 
appropriately the dual role of the immune system that not only prevents, but also 
shapes neoplastic disease (reviewed in 6). Cancer immunoediting can be 
considered as a result of three processes: elimination, equilibrium and escape 
(Figure 1), defined as the three “Es” of cancer immunoediting. The first phase, 
elimination, is the moment in which immunosurveillance occurs and the immune 
system is able to recognize and eliminate newly formed cancer cells. In the second 
phase, equilibrium, the Darwinian selection of tumor variants leads to the survival 
of the cancer cells endowed with low immunogenicity, that therefore have a better 
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chance to survive in the immunocompetent host. The alterations that occur during 
the immunologic sculpting of a developing tumor are probably facilitated by 
genetic instability of cancer cells. In this phase the tumor is not yet clinically 
apparent because the immune system is still able to control the growth of 
transformed cells. During the third phase of immunoediting, tumors become able 
to escape the immune control, to create an immunosuppressive tumor 
microenvironment and to grow in an uncontrolled manner becoming clinically 
relevant (reviewed in 6).  Work in the field of cancer immunoediting is now 
focusing on the study of the molecular mechanisms that drive the three processes 
and on the determination of the quality and quantity of tumor antigens expressed 
in newly transformed cells and that drive immune-mediated elimination and/or 
sculpting. This, in turn, should allow the development of new therapeutic 
strategies to facilitate the recognition and elimination of tumor cells by the 
immune system (reviewed in 7).     
 
Figure 1: The three phases of cancer immunoediting. 
The theory of cancer immunoediting comprises three processes. (a) Elimination 
corresponds to immunosurveillance. (b) Equilibrium is the phase in which immune 
system contains but not fully extinguishes tumor cells. During this process tumor variants 
with increased capacity to survive are selected. (c) Escape is the phase where selected 
tumor cells expand in an uncontrolled manner, avoiding the control of the immune 
system. In blue are represented developing tumor cells, in red tumor cell variants, in grey 
the stroma and nontransformed cells, in orange additional tumor variants. Taken from 
“Cancer immunoediting: from immuno-surveillance to tumor escape” (Dunn et al, Nature 
Immunology, 2002). 
 
1.2 Tumor immune tolerance 
In the last phase of cancer immunoediting, tumor cells are able to outgrow 
because they evade the control of the immune system. This is possible because 
during the equilibrium phase less immunogenic tumor variants are selected, but 
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also because tumor promotes a number of strategies that allow immune escape. 
One of these is represented by an impaired antigen presentation that can be due to 
down-regulation of the expression of tumor antigens 8-10, or to reduced MHC-I 
expression that prevents recognition of tumor cells by the immune system 11,12. 
Moreover, in some tumors, mutations of the antigen lead to an heterogeneity of 
tumor lesions that hinder the establishment of an efficient specific anti-tumor 
immune response 13. Another strategy triggered by tumors is the production of 
immunosuppressive factors 14,15 that can be secreted by the malignant cells 
themselves or by other cells of the tumor microenvironment such as immune, 
epithelial or stromal cells. Among these factors there are TGF-β, VEGF, 
prostaglandins, IL-10, macrophage-colony stimulating factor (M-CSF) and 
soluble tumor gangliosides (reviewed in 16). IL-10 and TGF-β can contribute, 
together with presentation of the tumor antigens by B cells to CD4+ T 
lymphocytes, to the deviation from a Th1 response, that is required for efficient 
tumor rejection, toward a Th2 humoral response 17,18. Also the production of 
indoleamine 2,3- dioxigenase (IDO), an enzyme that catalyzes the rate-limiting 
first step in tryptophan catabolism and overexpressed in response to IFN-γ in a 
variety of different malignancies, has immunosuppressive properties; in fact, the 
depletion of tryptophan from the tumor microenvironment has been shown to 
inactivate effector T cells and to promote the conversion of dendritic cells to 
immunosuppressive (reviewed in 19). Another strategy used by tumor to evade 
immune response concerns the change in expression of molecules that mediate 
apoptosis signalling, in order to avoid the killing mechanisms of the immune 
system. Moreover, tumors can adopt killing mechanisms proper of cytotoxic 
immune cells to delete the anti-tumor lymphocytes, a phenomenon called “tumor 
counter-attack” (reviewed in 16). T cells can be neutralized by tumor cells because 
tumors express molecules with inhibitory effect on T lymphocytes, such as B7-H1 
(reviewed in 20), HLA-G 21 and HLA-E 22, or through the induction of T cell 
anergy, a process that is induced when a T lymphocyte binds via its TCR to a 
peptide-MHC complex on the target cell without sufficient co-stimulation. 
Moreover, many tumors do not express costimulatory molecules and this may 
anergize anti-tumor T cells because of a lack of a proper co-stimulation signal 
(reviewed in 16). 
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Through all these mechanisms tumor can modify its microenvironment, creating 
an immunosuppressive milieu where many cell types are present and whose 
phenotype and function can be changed in order to favor tumor growth. Among 
these cells there are tumor-associated macrophages (TAMs) that mostly resemble 
M2 macrophages because M2 polarizing cytokines, such as IL-4 and IL-13, are 
common in tumors, but have properties that do not fit in a rigid classification of 
M1 and M2 macrophages 23. Their accumulation is associated with poor prognosis 
as they promote tumor growth, invasion, metastasis and angiogenesis through the 
release of cytokines, growth factors, extracellular-matrix (ECM) -degrading 
enzymes and angiogenic factors (reviewed in 24). EGF or RANKL (receptor 
activator of NF-kB ligand) secreted by tumors are the major mechanisms by 
which TAMs stimulate tumor dissemination (reviewed in 24). Similar to 
macrophages, tumor-associated neutrophils can be divided into N1 and N2 
phenotypes able to respectively inhibit or promote cancer development. TGF-β 
polarizes neutrophils towards a N2 phenotype 25 and these cells promote cancer by 
producing angiogenic factors and ECM-degrading enzymes 26,27 and by 
suppressing the antitumor immune response 28. Mast cells infiltrate hyperplastic 
lesions in the skin of K14-HPV16 transgenic mice and invasive fronts of 
carcinomas where they release proteinases that stimulate fibroblast proliferation 
and induce angiogenesis via MMP9 activation 29.  
Moreover, tumor secreted VEGF can stimulate immature dendritic cells (iDCs) 
which are recruited from the bone marrow to the tumor site 30 where they are 
functionally modulated and referred to as tumor associated-iDC (TiDCs) that are 
resistant to apoptosis and express the immunosuppressive enzyme IDO 31. 
Although TiDCs may capture tumour antigens derived from apoptotic cells and 
migrate to tumor-draining lymph nodes, they cannot present these antigens to 
naive T cells without amplification of co-stimulatory signals, resulting in immune 
tolerance 32. TiDCs, together with other immune cells and tumor-derived factors, 
can also induce a population of regulatory T cells (Treg) 33. Tregs are cells that 
normally play an indispensable role in the immune system as they are involved in 
the prevention of autoimmune diseases, allergies, infection-induced organ 
pathology, transplant rejection as well as graft versus host disease (GvHD) by 
suppression of effector T cells 34, however they can also dampen immune 
responses against tumors 35. Treg cells, together with myeloid-derived suppressor 
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cells (MDSCs), constitute one of the major player in tumor-induced 
immunesuppression.  
 
1.3 Myeloid derived suppressor cells (MDSCs) 
Myeloid –derived suppressor cells (MDSCs) are an immature myeloid population 
that originates from myeloid precursors present in the bone marrow, but unable to 
develop into terminally differentiated subsets, such as macrophages, granulocytes 
and dendritic cells, therefore retaining an immature phenotype, and acquiring the 
ability to suppress innate and adaptive immunity 36-38.  The current hypothesis is 
that MDSC expansion in peripheral lymphoid organs and recruitment to the tumor 
site depend on tumor-derived factors (TDFs), which comprise a variety of 
biologically active compounds, including growth factors, cytokines and 
chemokines, structured in a complex pattern of expression and reciprocal 
crosstalk 39. MDSCs, recruited during neoplastic growth, sustain tumor 
progression by providing a favourable microenvironment in which transformed 
cells can proliferate, acquire new mutations, expand and evade 
immunosurveillance. Moreover, MDSC subsets can take part in neoangiogenesis 
and metastatic spread 39.  
 
1.3.1 Factors involved in MDSC expansion 
Tumor cells can induce the expansion of MDSCs by means of different TDFs, that 
not only mobilize MDSCs, but may also limit their maturation and differentiation, 
thereby contributing to their accumulation 40. The difficulty in defining the crucial 
factors involved in MDSC recruitment is due to the fact that plasma cytokines and 
chemokines are different depending on the tumor type, resulting in tumor-
dependent MDSC proliferation, sites of accumulation and infiltration (reviewed in 
41). 
IL-6, IL-1β, granulocyte macrophage-colony stimulating factor (GM-CSF) and 
granulocyte-colony stimulating factor (G-CSF) found in the microenvironment of 
many tumors have been shown to significantly increase MDSC accumulation and 
T cell suppression (reviewed in 42). Prostaglandin E2 (PGE2) induces 
differentiation of c-kit+ hematopoietic stem cells into MDSCs, contributing to T 
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cell immunosuppression 43,44. In addition, the pro-inflammatory proteins 
S100A8/A9 induce MDSC accumulation 45. An autocrine positive feedback loop 
is created by MDSC secreting pro-inflammatory factors, including IL-6 and 
S100A8/A9, thus further sustaining themselves in the tumor microenvironment 
45,46
. Tumor necrosis factor (TNF) impairs MDSC maturation by regulating the 
receptor for advanced glycation end products (RAGE) and its ligands 
(S100A8/A9) 47. Other factors, such as VEGFA (reviewed in 41), stem cell factor 
(SCF, also known as KIT ligand) 48, FMS-like tyrosine kinase 3 ligand (FLT3L) 49 
and M-CSF 50 have been shown to be secreted by tumors that stimulate MDSC 
proliferation. Also the complement system, in particular C5a, has been shown to 
be involved in MDSC expansion by attracting them or increasing their activity 51. 
Among all these factors, on three of them there is strong evidence about their 
involvement in MDSC recruitment and expansion: GM-CSF, G-CSF and IL-6. In 
fact, it has been demonstrated that silencing GM-CSF in a mammary carcinoma 
model determined a reduction in the accumulation of MDSCs and in the systemic 
immunosuppression induced by this tumor 52. GM-CSF also appears to assume a 
key role in MDSC expansion in cancer patients, since melanoma patients who 
received GM-CSF as an adjuvant, together with a vaccine, expanded an MDSC 
population which suppressed PBMC proliferation in a TGF-β dependent fashion 
53
.  
The key role of G-CSF in regulating MDSC expansion is proved by the fact that it 
is present at high level in the sera of mice implanted with AT-3 and 4T1 
mammary cancer and the treatment with anti-G-CSF mAb or down-regulation of 
G-CSF expression by RNA interference led to a significant reduction of MDSCs 
54
.  
Another group showed instead that IL-6 promoted tumor progression by 
enhancing the accumulation of MDSCs acting as downstream mediator of the IL-
1β signaling, an established TDF that triggers MDSC generation 55.  
 
1.3.2 Murine MDSCs  
From the early observations in tumor-bearing mice, MDSC phenotype has been 
defined on the basis of the co-expression of CD11b and Gr-1 markers 56,57 and 
later as CD11b+ /Gr-1+ /IL4Rα+ /CD11c-/F4/80+/-58. However, such cells are not a 
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homogeneous cell population, and in fact, more recently, on the basis of  Gr-1, 
Ly-6G, Ly-6C and CD49d expression, two main subsets were described: 
granulocytic, CD11b+/Gr-1hi/Ly-6Clow/Ly-6G+/CD49d- MDSCs (G-MDSCs or 
PMN-MDSCs) and CD11b+/Gr-1int/Ly-6Chi /Ly-6G-/CD49d+, monocytic MDSCs 
(Mo-MDSCs) 52,59,60. G-MDSCs suppress antigen (Ag)-specific CD8+ T cells 
mainly by producing reactive oxygen species (ROS), while Mo-MDSCs act 
primarily by expressing nitric oxide syntase (NOS)2 and arginase (ARG)1 
enzymes and generating reactive nitrogen species (RNS) 61. The proportion of G-
MDSCs and Mo-MDSCs is highly variable in different tumor models but the 
factors regulating their distribution are not entirely known. However, in most 
tumor models the majority of MDSCs in peripheral lymphoid organs are G-
MDSCs but the ratio between G-MDSCs and Mo-MDSCs is much lower at tumor 
sites 62.  
 
1.3.3 Human MDSCs  
MDSCs have been extensively studied in the last years given their role in 
breaking down the immune responses under many pathological conditions, 
including cancer. However, the fact that MDSC expansion in cancer patients can 
be induced by many different factors, depending on the tumor type but also on 
individual factors, and the lack of a cognate Gr-1 antigen in humans has led to the 
definition of many different MDSC subsets  leading to a great heterogeneity 
(Table 1). However, three major subsets of MDSCs can be distinguished in cancer 
patients: monocytic MDSCs (Mo-MDSCs), granulocytic MDSCs (G-MDSCs), 
and immature MDSCs, although other myeloid subpopulations have been 
described 63 41. Monocytic MDSCs are CD14+ and granulocytic MDSCs express 
CD15, while both subsets express the common myeloid markers CD11b and 
CD33 64. Our group demonstrated the expansion of two MDSC subsets, one 
belonging to CD14+ monocytes, the other to CD15+ PMN, in the peripheral blood 
of melanoma and colorectal cancer patients. These subsets expressed the alpha 
chain of IL-4 receptor (IL4Rα) at higher levels as compared to the same cells 
isolated from healthy donors, but the presence of this marker positively correlated 
only with the immunosuppressive activity of monocytes, but not of granulocytes 
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65
. These data are in agreement with a previous study in which it was 
demonstrated that IL4Rα is a marker for murine MDSCs 66 .  
Immature MDSCs are mainly defined as Lin−/HLA-DR−/CD33+/CD11b+ 67. 
Lineage (Lin) cocktail is a mixture of antibodies that contains markers 
progressively up-regulated during hematopoietic commitment. Lin thus allows the 
distinction of uncommitted cells (Lin-) from their more mature counterparts 
(Lin+).  
More recently, a novel subset was added to MDSC family, documented in 
metastatic cancer patients. These cells were named F2 fibrocytes, because they 
bore the phenotypical and functional hallmarks of fibrocytes but were able to 
inhibit T cell response via indolamine 2,3 oxygenase (IDO) 68.  
 
 
 
Table 1. Phenotype of MDSCs in human malignancies. Modified from “Myeloid-derived 
suppressor cells in cancer patients: a clinical perspective” (Montero et al., Journal of 
immunotherapy, 2012) 
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MDSC levels have been shown to correlate negatively with prognosis and overall 
survival (OS) in cancer patients and the accumulation of this population appears 
to contribute to tumor progression. Recently, human MDSCs have also been 
proposed as biomarkers associated to either survival or disease progression. 
However, the main difficulty of these studies depends on a lack of consensus on 
MDSC phenotype or, rather, on the increasing number of different phenotypes 
documented in several tumors of different origins 63. Recently, by taking into 
account all the reported myeloid subsets endowed with suppressive activity, a 
recent study identified six human MDSC phenotypes (MDSC1-MDSC6) using a 
single multicolor staining: MDSC1 (CD14+/IL4Rα+), MDSC2 (CD15+/IL4Rα+), 
MDSC3 (Lineage-/HLA-DR-/CD33+), MDSC4 (CD14+/HLA-DRlow/-), MDSC5 
(CD11b+/CD14-/CD15+) and MDSC6 (CD15+/FSClow/SSChigh) 69. With the 
exception of MDSC1, all other MDSC subsets were significantly higher in RCC 
patients than in healthy controls. Furthermore, MDSC4 and MDSC5 subsets were 
negatively associated with overall survival of RCC patients treated with 
cyclophosphamide and IMA901, a multipeptide vaccine designed for RCC 
immunotherapy 69.  
Given the clear discrepancies in documenting human MDSC phenotype, a 
phenotyping proficiency panel, to which our group is actively participating, is 
ongoing under the guidance of the association of Cancer Immunotherapy 
Immunoguiding Program (CIP) in order to reach the harmonization of MDSC 
immunophenotyping across different groups. This will help to rearrange all the 
knowledge in the field and will also facilitate clinical application of MDSC 
screening.  
 
1.3.4 Mechanisms of action of MDSCs 
Over the years, several mechanisms have been described by which MDSCs are 
able to suppress T-cell responses. One of these involves the depletion of 
aminoacids such as L-arginine (L-Arg), L-cysteine and L-phenylalanine. The two 
major catabolitic enzymes through which MDSCs metabolize L-Arg are arginase, 
that converts L-Arg into urea and L-ornithine, and NOS that which oxidizes L-
Arg generating NO and citrulline. ARG1 and NOS isoforms were reported to be 
expressed by MDSCs (reviewed in 70) and ARG1 was found up-regulated also in 
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plasma of cancer patients 71.  MDSCs were shown to play a role as L-cysteine 
consumers/sequesters since these cells import the aminoacid but do not express 
the transporter to release it in the extracellular milieu 72. Moreover, human and 
mouse MDSCs can express IL4 induced 1 (IL4I1), a secreted L-phenylalanine 
oxidase that produces hydrogen peroxide (H2O2) and phenylpyruvate following 
oxidative deamination of phenylalanine 66,73. Depletion of these aminoacids from 
the microenvironment is involved in immunoregulation since the lack of L-Arg 
causes an arrest of T cells in G0-G1 phase and the sequestration of L-cysteine 
inhibit T cell activation, proliferation and differentiation (reviewed in 42). Both 
depletion of L-Arg and the metabolism of phenylalanine can lead to the 
production of H2O2 that can inhibit CD3ζ chain expression and T cell proliferation 
73
, effects mediated also by deprivation of L-arginine 74. Production of reactive 
oxygen species (ROS), such as H2O2, is a mechanism that greatly affects immune 
regulation by inhibiting T cell proliferation. MDSCs can increase the presence of 
ROS in tumor microenvironment by the expression of NOX2, the catalytic subunit 
(also known as gp91phox) of NADPH oxidase 75 that reduces oxygen to 
superoxide anion using electrons supplied by NADPH 76. Another mechanism 
involved in generation of ROS by MDSCs implies the co-expression of ARG and 
NOS2, in fact the limited availability of L-Arg produced by ARG induce NOS2 to 
produce superoxide anion. When superoxide anion interacts with NO, reactive 
nitrogen species (RNS) can be generated 77.  The latter are able to nitrate tyrosine 
residues in the TCR and CD8 receptors, thus resulting in a decreased recognition 
of peptide-MHC complexes by the TCR 78. The importance of RNS in the tumor 
context was highlighted by a study in which it was demonstrated that CCL2, an 
inflammatory chemokine involved in the recruitment of both CTLs and myeloid 
cells to tumors, can be modified in the tumor microenvironment by RNS. Such 
alteration is a stable posttranslational modification, that changes CCL2 functional 
properties resulting in an impaired capacity of T cells to bind the modified 
chemokine. As a result, nitrated CCL2 loses its ability to recruit tumor-specific 
CTLs, while retaining its ability to attract myeloid cells to the tumor 79. 
Concerning the role of transcription factors, our group demonstrated that the 
immunosuppression exerted by MDSCs depends on CCAAT-enhancer binding 
protein-β (C/EBP-β). In fact, silencing of this transcription factor by short-hairpin 
RNA allowed to restore the proliferation of activated T cells co-cultured with 
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silenced MDSCs 80. Moreover, studies in murine models performed by our group 
recently demonstrated that the expression of LAP*, one of the 3 isoforms of 
C/EBP-β, can be regulated by miR-142-3p, by non-canonical binding to its 5’ 
mRNA coding sequence. MiR-142-3p up-regulation decreased LAP* expression, 
but also reduced the activation of STAT3. In fact, the  canonical binding of the 
miRNA to the 3’ UTR of IL6st decreased the expression of this protein, that is 
one of the subunits of the IL-6 cytokine receptor upstream of STAT3. Through the 
described mechanisms, miR-142-3p up-regulation reduced the 
immunosuppressive activity of MDSCs, by impairing their differentiation toward 
the monocytic-macrophage subset, that in mice is endowed with the strongest 
immunosuppressive activity 81.  
MDSCs can induce immunosuppression also by releasing IL-10. This cytokine, 
exerts several immunosuppressive effects: it drives the development of a Th2 
response, can enhance Treg cell activity, inhibits TLR-induced IL-12 production 
by DCs and reduces DC-mediated activation of T cells 58. 
MDSCs isolated from gastric cancer patients were reported to secrete S100A8/A9 
molecules, when cultured with activated T cells. Interestingly, addition in the 
culture of agents inhibiting the S100A8/A9 molecules and their receptor RAGE 
restored T cell function and proliferation in the cultures 82.  
Moreover, a recent work reported the expansion of CD14+/HLA-DRlow/- MDSCs 
in patients who underwent allo-hematopoietic stem cell transplantation after 
hematological malignancies and the immunosuppression mediated by these cells 
depended on IDO expression, since IDO inhibition significantly enhanced T cell 
proliferation in vitro 83.  
Moreover MDSCs can indirectly induce immunosuppression through induction of 
Tregs  expansion 84 and by converting anti-tumor M1 cells into tumor-promoting 
M2 cells by producing IL-10 and reducing macrophage production of IL-12 
(reviewed in 58).   
 
1.3.5 MDSCs as a therapeutic target  
Given their clinical relevance in cancer patients, MDSCs become an interesting 
therapeutic target. MDSC inhibitors used so far in clinical studies for cancer 
patients can be divided into three classes according to their ability to: i) promote 
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MDSC differentiation into mature non-suppressive cells, ii) decrease MDSC 
levels, iii) functionally inhibit MDSCs (reviewed in 42).   
Promoting differentiation of suppressive MDSCs into mature, non-suppressive 
cells has been considered a way to neutralize immunosuppressive properties of 
MDSCs and enhance anti-tumor immune responses. All trans retinoic acid 
(ATRA), a derivative of vitamin A, has been shown to induce MDSC 
differentiation by a glutathione synthase dependent mechanism 85. ATRA induced 
differentiation of MDSC into myeloid dendritic cells in vitro and in vivo, but it did 
not decrease tumor burden 37. Better results were instead obtained combining 
ATRA with antigen specific peptide vaccines in two different tumor models 86. In 
metastatic RCC patients with elevated MDSC levels, treatment with ATRA was 
effective in reducing MDSC number only when it reached a high plasma 
concentration (>150 ng/ml) 87. Also treatment with vitamin D3 was shown to 
reduce the number of immunosuppressive CD34+ cells in patients with HNSCC 88.  
Sunitinib, an oral receptor tyrosine kinase inhibitor that targets signaling by 
PDGFRs, VEGFRs and c-kit and that was approved for the treatment of advanced 
RCC was shown to reduce MDSCs levels. In fact, sunitinib treatment of RCC 
patients augmented T cell response in association with a decrease in MDSC 
levels, including a reduction in the dominant population, G-MDSCs 89. Additional 
studies in a mouse tumor model (4T1) indicate that sunitinib treatment may 
induce apoptosis in the granulocytic MDSC subset  90. Other studies on a murine 
kidney cancer model (RENCA) showed that it may act through inhibition of 
STAT3 and of STAT3 regulated pro-angiogenic genes in MDSCs 91,92.  
Gemcitabine, a cytidine nucleoside analog, has been shown to decrease splenic 
MDSCs in murine models of five advanced lung cancer cell lines. An increase in 
the anti-tumor activity of CD8+ T cells and in the activation of NK cells was 
noted, making this a promising MDSC targeting agent. Moreover, at specific time 
points after treatment, gemcitabine was shown to selectively induce MDSC’s 
apoptosis 93.  
5-FU, a pyrimidine analog, is another chemotherapeutic agent that has shown 
selective anti-MDSC activity. In mouse tumor models, 5-FU showed efficacy in 
MDSC depletion by induction of apoptosis, leading to increased IFN-γ production 
by tumor-specific CD8+ T cells infiltrating the tumor and promoting T cell-
dependent anti-tumor responses in vivo 94.  
 23
Moreover VEGF over-production was reported in RCC cancer patients, so 
treatment of tumor bearing mice with anti-VEGF-1 mAb was performed and it 
was observed that it caused a reduction of MDSC levels. Unfortunately, the same 
effect was not reported in RCC patients treated with the antibody alone or in 
combination with IL-2 95,96.  
Phosphodiesterase type 5 (PDE-5) inhibitors, COX-2 inhibitors, CDDO-Me and 
nitroaspirin have been evaluated as functional inhibitors of MDSCs. In multiple 
murine tumor models treatment with PDE-5 inhibitors not only increased CD8+ T 
cell intratumoral infiltration, but also dampened MDSC suppressive pathways 
through the down-regulation of  ARG1, NOS2 and IL4Rα. Interestingly, PDE-5 
inhibitors restored T cell proliferation also in cancer patients 97.  
The enzyme cyclooxigenase 2 (COX-2) plays a role in the production of PGE-2, 
which induces MDSC expansion 44. In a murine glioma model, treatment with 
COX-2 inhibitors inhibited systemic PGE-2 production and decreased MDSC 
level both in the bone marrow and the tumor microenvironment 98. Moreover it 
was shown that PGE-2 attracts MDSC into the ascites microenvironment of 
ovarian cancer patients by inducing expression of CXCR4 in MDSCs and playing 
a role in the production of its ligand CXCL12, thus ensuring MDSC migration. In 
fact, MDSC frequencies closely correlated with CXCL12 and PGE-2 levels in 
ascitic fluid 99. 
CDDO-Me belongs to the class of synthetic triterpenoids and has been shown to 
up-regulate several antioxidant genes. Since production of ROS is a mechanism 
used by MDSCs, it was expected that this drug could have an effect on their 
activity. In fact, treatment of mice with this agent eliminated MDSC-mediated 
immunosuppression and CDDO-Me added in vitro to MDSCs isolated from RCC 
patients was able to inhibit their activity 100.  
Another compound able to interfere with the mechanisms of action of MDSCs is 
nitroaspirin, developed by coupling a NO-releasing moiety to aspirin. This drug is 
able to inhibit both NOS and ARG activity and to reduce the nitration of proteins 
within the tumor microenvironment. The immune stimulating effect of 
nitroaspirin however was evident only when it was combined with active 
immunotherapy 101. As for nitroaspirin, other drugs showed ehnanced activity 
when used in combination. The current strategies of cancer therapy in fact are 
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aimed to combine approaches that reduce MDSCs as an adjuvant to different 
forms of immunotherapy (reviewed in 42).   
 
1.3.6 In vitro induction of MDSCs from BM cells 
Our group demonstrated that MDSCs can be induced in vitro from human and 
murine bone marrow (BM) cells cultured with the combination of cytokines G-
CSF+ GM-CSF and GM-CSF+ IL-6 80. CD11b and CD16 markers were used to 
evaluate the phenotypes of the cultures as they allow to distinguish the 
differentiation stages of myeloid cells because the expression of these two 
molecules increases with the progressive commitment of BM cells. The treatment 
of BM with the above mentioned cytokines, in particular with the combination G-
CSF+GM-CSF, gave rise to a cell population with an heterogeneous pattern of 
maturation ranging from promyelocytes to mature granulocytes, but with a 
significant increase in more immature CD11b+CD16- cells as compared to other 
combinations of cytokines or untreated BM 80. Moreover, BM cells treated with 
G-CSF+GM-CSF had the highest expression of IL4Rα, that we demonstrated to 
be a marker of human MDSCs. We also evaluated the immunosuppressive activity 
of these cells and, as they were able to inhibit both mitogen-activated and 
alloantigen-stimulated T cells, we named them BM-derived MDSCs (BM-
MDSCs) 80. Our group also demonstrated that the immunosuppressive activity of 
BM-MDSCs is due to CCAAT-enhancer binding protein beta (C/EBPβ) 80, a 
transcription factor that controls emergency granulopoiesis induced by cytokines 
and infection 102. Further characterization of the mechanisms of action of these 
cells revealed that BM-MDSCs can induce a significant reduction in the 
intracellular levels of CD3ζ chain in co-cultured CD8+ T cells 103, moreover, the 
inhibitory effect on T cell proliferation was evident only in the presence of a cell-
to-cell contact and the immunosuppressive capacity of BM-MDSCs is enhanced 
in the presence of strongly activated T lymphocytes 103.    
 
Since BM-MDSCs are a very heterogeneous population, we further characterized 
them by separating, through FACS sorting, three subsets at different stages of 
maturation, based on the expression levels of CD11b and CD16 antigens. Testing 
the immunosuppressive activity of these subsets, we observed that only the most 
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immature CD11blow/-/CD16- cell population (iBM-MDSCs) was able to block 
lymphocyte proliferation and to affect IFN-γ production, while the other two 
subsets of BM-MDSCs were completely devoid of suppressive activity 103. iBM-
MDSCs had a morphology similar to that of promyelocytes, however, the same 
population isolated from fresh BM cells completely lacked suppressive activity. 
Flow cytometry analysis revealed that iBM-MDSCs  did not express the 
monocytic marker CD14 while such cells expressed the CD15 granulocytic 
antigen 103. Moreover, they were negative for lineage markers and expressed the 
myeloid marker CD33. Two discrete populations with different expression of 
HLA-DR (low or negative) were noted 103. This phenotype was similar to that of 
MDSCs previously described in tumor-bearing patients 67 104. Indeed, in the blood 
of patients with stage IV breast or colorectal cancer we could identify a Lin-/HLA-
DR-/CD33+/CD11b+ MDSC population resembling in vitro-generated BM-
MDSCs and increased levels of these cells correlated with worse prognosis and 
radiographic progression 103. 
 
Further analysis of the suppressive subset of BM-MDSCs was performed after co-
culture with either resting or activated T cells since the activation level of T 
lymphocytes appeared to be critical to drive the suppressive activity of BM-
MDSCs. We observed that the presence of activated T cells was able to increase 
the proliferation of iBM-MDSCs and also to maintain their immature phenotype, 
as shown by the levels of expression of CD11b and CD16 markers (Figure 7). We 
also observed that the expression of the markers HLA-DR and CD34 were 
maintained or even increased, in the presence of activated T cells, while CD66b 
was down-regulated. Control cultures of immature BM-MDSCs alone or in the 
presence of resting T cells followed instead the default maturation program, thus 
highlighting that only the presence of activated T cells is able to block the 
differentiation process of iBM-MDSCs and suggesting the existence of an 
interplay between MDSCs and activated T cells (Figure 2) 103.  
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Figure 2: T lymphocyte activation maintains the immature phenotype of iBM-
MDSCs 
Flow cytometric evaluation of CD11b, CD16, HLA-DR, CD34 and CD66b markers in 
the immature subset of BM-MDSCs. Analysis was performed before and after the co-
culture of iBM-MDSCs with either resting or anti-CD3/CD28-activated T cells. The 
expression of the markers was compared to the autofluorescence signal (black histogram). 
Taken from “A human promyelocytic-like population is responsible for the 
immune suppression mediated by myeloid-derived suppressor cells” (Solito et al, 
Blood, 2011). 
 
 
1.4 Signal Transducer and Activator of Transcription 3 (STAT3): a 
key factor in promoting tumor growth 
STAT3 is implicated in a series of processes that favor tumor growth, as it is 
involved in cell proliferation and transformation, it suppresses apoptosis and can 
mediate cellular invasion, angiogenesis and metastasis and has a role in 
chemoresistance and radioresistance (reviewed in 105). Moreover, it mediates 
tumor-induced immunosuppression at different levels, since STAT3 activity in 
tumor cells can negatively influence the expression of pro-inflammatory cytokines 
and chemokines 106 and inversely correlates with immune-cell migration in vitro 
and infiltration into tumours in vivo 107. STAT3 activation in tumor cells 
negatively affects DC functional maturation by suppressing the expression of 
MHC-II and of co-stimulatory molecules and IL-12 secretion through the 
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production of IL-10 and VEGF that in turn activate STAT3 in DCs, leading to an 
arrest in their maturation 106. Moreover, STAT3 signalling can inhibit immune 
stimulation in macrophages 108 and anti-tumor cytotoxic activity in NK and 
neutrophils 109, while its activation in Treg cells is important for their proliferation 
and for the suppression of tumour-specific CD8+ effector T cells 109. A role for 
STAT3 was reported also in MDSCs expansion and activity. In fact, it was 
demonstrated that MDSCs isolated from tumor bearing mice have increased levels 
of phosphorylated STAT3, as compared to immature myeloid cells from healthy 
mice,110 and that the expansion of MDSCs is abrogated when STAT3 is inhibited 
in hematopoietic progenitor cells 111. Moreover, STAT3 can also induce the 
expression of S100A8/A9 in murine myeloid cells, molecules that induce MDSC 
accumulation and prevent their differentiation 47. All these data highlight the 
importance of STAT3 signalling in tumor progression since it is activated in both 
tumors and tumor-infiltrating immune cells.   
From the molecular point of view, STAT3 is a 92-kDa protein, 770 amino acids 
long with sequential N-terminal coiled-coil domain, DNA-binding domain, a 
linker, SH2 domain and C-terminal transactivation domain. The latter contains a 
tyrosine residue at position 705 and a serine residue at position 727, which 
undergoes phosphorylation when activated (Figure 3). STAT3 activation is driven 
by: i) many cytokines, such as IL-6  and IL-10; ii) growth factors, including G-
CSF  and GM-CSF; iii) oncogenic proteins such as Src and Ras (reviewed in 105). 
The activation of STAT3 is regulated by receptor and non-receptor protein 
tyrosine kinases, such as epidermal growth factor receptor (EGFR) kinase, Src, 
Janus-activated kinases (JAK) and extracellular signal-regulated kinase (ERK) 
(reviewed in 105),  that phosphorylate STAT3 at Tyr705 in the cytoplasm leading 
to its dimerization, translocation into the nucleus, and DNA binding 112; this, in 
turn, leads to the expression of genes that regulate cell proliferation, 
differentiation and apoptosis. Other serine kinases, including protein kinase C 
(PKC) and mitogen-activated protein kinases, have been implicated in the 
phosphorylation of STAT3 at serine 727, which maximizes its transcriptional 
activity 105,113. Besides phosphorylation at sites within the carboxyl-terminal 
region, STAT3 is also acetylated on a single lysine residue 685 by histone 
acetyltransferase p300, a modification that can be reversed by type I histone 
deacetylase (HDAC) 114. The acetylation of STAT3 is critical to form stable 
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dimers, which are required for cytokine-stimulated DNA binding and 
transcriptional regulation. STAT3 activation is instead negatively regulated 
through numerous mechanisms that include the suppressors of cytokine signaling 
(SOCS), protein inhibitor of activated STAT (PIAS), protein phosphatases and 
ubiquitination-dependent proteosomal degradation (reviewed in 105).       
STAT3 exists in two isoforms, the full length STAT3α (92 kDa) and the truncated 
STAT3β (86 kDa), generated by alternative mRNA splicing in exon 23 115. 
STAT3β lacks the 55-residue C-terminal trans-activation domain, containing 
Ser727, that is substituted by a unique 7 residue sequence (CT7) whose function is 
still unknown 116. However, it was demonstrated that, although STAT3α has a 
greater transcriptional activity, STAT3β binds more efficiently to DNA, forms 
more stable dimers, due to the lack of the C-terminal acidic region, and has a 
more prolonged nuclear retention, likely due to its unique C-terminal domain, in 
addition to a reduced intranuclear mobility, especially upon cytokine stimulation 
116,117
.  
 
 
Figure 3: Structure of STAT3 α and β isoforms.  
Modified from “Signal transducer and activator of transcription (STAT) signalling and T-
cell lymphomas” (Mitchell and John, Immunology, 2005) 
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1.5 The B7- family of proteins: surface molecules involved in the 
modulation of immune response  
 
The B7-family consists of structurally related, cell-surface proteins that regulate 
immune responses by interacting with their ligands expressed on the surface of T 
cells (Figure 4). Until today, nine family members have been identified that 
include CD80 (B7-1), CD86 (B7-2), CD274 (programmed cell death-1 ligand 
(PD-L1)/B7-H1), CD273 (programmed cell death-2 ligand (PD-L2)/B7-DC), 
CD275 (inducible costimulator ligand (ICOS-L)/B7-H2/B7RP-1/B7h), CD276 
(B7-H3), B7-H4 (B7-S1/B7x) and B7-H6 (reviewed in 118 119).  The importance of 
B7- family members in regulating immune responses is due to their capacity to 
deliver co-stimulatory or co-inhibitory signals to T cells. In fact, the activation of 
T cells is induced upon the interaction of the TCR with the specific peptide/MHC, 
but requires also a second signal given by the antigen presenting cell (APC) (co-
stimulation). When co-stimulation is not engaged and signaling occurs through 
TCR alone, a state of anergy or apoptosis is induced 120. Besides these activatory 
signals, inhibitory co-stimulatory receptors promote negative stimuli and their 
balance influences T lymphocyte activation and the maintenance of peripheral 
tolerance 121,122. If such balance is impaired, autoimmune conditions may arise 123. 
Classically, CD80 and CD86 expressed on the surface of APC interact with the 
co-receptor CD28 that is constitutively expressed on the surface of T cells. The 
effect of CD28 ligation is to increase the level of proliferation and cytokine 
production, promote cell survival and enhance expression of CD40 ligand 
(CD40L) and adhesion molecules necessary for trafficking (reviewed in 119). 
Limited expression of CD80 and CD86 on APCs is a mechanism for maintenance 
of peripheral T cell tolerance, ensuring that T cells activation can only be 
stimulated by appropriate cells 124. After activation, T cells express CTLA-4, a 
close homologue to CD28, but with a higher affinity of binding to members of the 
B7 family 125. CTLA-4 is an inhibitory membrane receptor expressed exclusively 
on T cells, where it primarily regulates the amplitude of the early stages of T cell 
activation, by competing with CD28 for binding to CD80 and CD86 (reviewed in 
126).   
Another inhibitory receptor expressed by T cells is PD-1, a type 1 transmembrane 
glycoprotein of the Ig superfamily, with an extracellular domain showing 21-33% 
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sequence identity with CTLA-4, CD28 and ICOS molecule, but with distinct 
function and ligand specificity. Two ligands for PD-1 have been identified on the 
basis of similarity to other B7 superfamilies: PD-L1 and PD-L2, two type 1 
transmembrane glycoproteins composed of IgC and IgV-type extracellular 
domains that present 40% amino acid identity  (reviewed in 127). PD-L1 is more 
broadly expressed on immune and non-hematopoietic cells, specifically it is 
constitutively expressed on T and B cells, macrophages and dendritic cells and it 
is upregulated upon stimulation by proinflammatory cytokines such as IFN. In 
contrast, PD-L2 expression is limited to the medullary region of the thymus and, 
at low level, on fetal myocardium and endothelial cells, while it is strongly 
expressed in placental endothelial cells 128. PD-L2 can be induced on several cell 
types, such as DCs, peritoneal B1 B cells, macrophages, BM-derived mast cells 
and memory B cells (reviewed in 129). Although PD-L1 expression is wider than 
that of PD-L2, PD-L2 can bind PD-1 with a higher affinity than PD-L1 and 
appears to have an additional, but yet unidentified receptor (reviewed in 119). The 
concomitant binding of PD-1 by PD-L1 or PD-L2 during TCR activation induces 
blockade of B and T cell proliferation, secretion of cytokines, inhibition of 
cytolytic function and influences T cell survival (reviewed in 129).  
Another couple of receptor-ligand that can give co-stimulatory signals to T cells is 
constituted by ICOS, a CD28-like molecule expressed only on activated T cells, 
and ICOSL (also called B7-H2/B7RP-1/B7h), a protein with structural similarities 
to CD80/CD86 that, in fact, signals by binding to its receptor, but also via CD28. 
ICOSL is constitutively expressed by APCs and in non-haematologic tissues and 
is down-regulated with ongoing inflammation, in contrast to the activation-
induced CD28 ligands (reviewed in 118). Although involved in maintaining 
durable immune reactions, ICOS has a controversial role in T cell regulation, 
because it favours IL4/IL10/IL13 and humoral responses at the expense of IFN-γ-
mediated cytotoxic/Th1 responses. Moreover, it plays a role in maintaining 
immunosuppressive CD4+ T cell subsets secreting more IL-10, and is an essential 
factor, together with FOXP3, for proper Treg development (reviewed in 118).  
B7-H3 protein can be expressed by dendritic cells and in several normal lymphoid 
and peripheral tissues 130, but its expression was reported to be elevated also in 
numerous types of cancer 131. However, the physiological and pathological role of 
B7-H3 is largely unknown. It was reported to be a co-stimulator of T cells, 
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promoting T cell proliferation and cytokine production 132, but more recently B7-
H3 was described as a potent inhibitor of T cell activity 133. In contrast to these 
studies, Steinberg and colleagues suggested that B7-H3 has no characteristics of a 
co-signaling molecule and does not act as a regulator of immune responses134. 
Conflicting findings may be due to the existence of two isoforms of B7-H3: one 
with four Ig-like domains in the extracellular domain and one with two Ig-like 
domains in the extracellular domain due to alternative splicing 135 136. The 
expression patterns of each isoform in tumors and the mechanism by which the 
two isoforms affect cancer progression remain unknown. However, Sun and 
colleagues recently reported a negative correlation both between the expression 
levels of B7-H3 and the survival time of patients with non-small cell lung cancer 
and (NSCLC) and between B7-H3 expression and the levels of tumor-infiltrating 
macrophages, suggesting a role in immunosuppression in cancer patients137.   
B7-H4 was identified as a co-inhibitory member of the B7 family. In humans, B7-
H4 mRNA is found in many organs, with little protein expression that can be 
induced in monocytes, macrophages and dendritic cells upon IL-6 and IL-10 
stimulation 138-140. B7-H4 transcripts and proteins are overexpressed in many solid 
tumors to varying extent (reviewed in 20) and there is evidence that B7-H4 can 
promote tumor growth, although the mechanism of action and its receptor on T 
cells are still unkonown141 142. A study revealed a dual role of B7-H4, because 
they confirmed the negative regulation on Th1- mediated antitumor immunity, but 
they also reported an inhibition of MDSCs, underlying the opposite effects of this 
molecule on immune system143. 
A recent study  has described HERV-H LTR-associating protein 2 (HHLA2) as a 
member of the B7 family that shares 10-18% amino acid identity and 23-33% 
similarity to other human B7 proteins and philogenetically forms a subfamily with 
B7-H3 and B7-H4 144. It is the only molecule that is expressed in humans, but not 
in mice, in particular it is constitutively present on the surface of monocytes and it 
is induced on B cells after stimulation with LPS and IFN-γ. HHLA2 does not 
interact with other members of the family, but binds a putative receptor expressed 
on T cells and APCs, inhibiting T cell proliferation and cytokine production.  
Another member of the family is B7-H6, a PD-L1/B7-H3 homologue that 
specifically binds the NK-effector molecule NKp30, leading to NK activation. 
B7-H6 is not expressed in any normal tissue, but it is present in a variety of 
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primary tumors and cell lines 145 and its expression was reported to be dependent 
on hystone deacetylase 3 (HDAC3), thus suggesting a new potential strategy for 
cancer treatment 146.  
Besides the molecules listed before, there are also newer potential members of the 
B7 family, that have been identified via in silico screening over the last few years.  
One of these is V-domain Ig suppressor of T-cell activation (VISTA) that is 
primarily expressed on hematopoietic cells and highly upregulated on APCs and 
CD4+ T cells. Data show that a soluble VISTA-Ig fusion protein or VISTA 
expression on APCs inhibits T cell proliferation and cytokine production. 
Moreover, overexpression of this molecule on tumor cells interferes with 
protective antitumor immunity in vivo in mice, thus suggesting that it could have a 
role in immune suppression in cancer 147.  
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Figure 4: B7/CD28 family members 
B7 family proteins provide co-stimulatory and co-inhibitory signals to T cells. This is 
classically illustrated by CD80/CD86-CD28 interaction, that delivers a co-stimulatory 
signal, in comparison to CD80/CD86- CTLA-4 interaction that instead delivers a co-
inhibitory signal. Other B7 family members have been identified that are PD-L1, PD-L2, 
ICOSL, B7-H3 and B7-H4 with activating or inhibiting functions on T cells. Besides 
these molecules, there are also newly described potential family members like V-domain 
IG suppressor of T-cell activation (VISTA) and Cgen-1500T. B7-H6 is expressed by 
tumor cells and interacts with NKp30 on NK cells. Taken from “Targeting the B7 Family 
of Co-Stimulatory Molecules: successes and challenges” (Podojil and Miller, BioDrugs, 
2013). 
 
1.6 Functional role of PD-1/PD-L1 interaction in tumors 
The discoveries that PD-L1 is constitutively expressed in many human cancers 
and that PD-1 is expressed in TILs (reviewed in 127) have highlighted the possible 
role that these molecules could have in the induction of tumour tolerance. In fact, 
the interaction of PD-L1 with its receptor PD-1 on T cells causes an impairment 
of T cell function through induction of apoptosis, anergy or exhaustion (reviewed 
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in 20), inhibition of T-cell cytokine release, such as IFN-γ, IL-4, and IL-2 
(reviewed in 129), thereby inducing the production of the immunosuppressive 
cytokine IL-10. PD-1/PD-L1 interaction can also influence Treg generation and 
their suppressive properties 148. Moreover, PD-L1 was reported to be involved in 
MDSC mechanism of action and in their crosstalk with T reg cells 149. All these 
mechanisms favour the formation of an immunosuppressive milieu that thus 
facilitates tumor progression. In fact, PD-L1 expression on TILs was significantly 
associated with poor prognosis in renal cell carcinoma patients 150, a result 
confirmed also in patients with oesophageal, gastric and ovarian cancers 
(reviewed in 20) and some reports have shown that PD-L1 expression on tumour 
cells can be associated with decreased numbers of TILs in cancer patients. These 
observations opened the possibility to interfere with PD-L1 signalling by blocking 
the interaction with its receptor. Two large clinical trials of anti-PD-1151 and anti-
PD-L1 neutralizing antibodies 152 showed that blocking these immunoregulatory 
proteins induced durable tumor regression and prolonged disease stabilization in 
patients with selected advanced cancers, including NSCLC, a tumor considered to 
be non-responsive to immunotherapy.    
 
1.7 T cell anergy, exhaustion and senescence in tumor 
microenvironment 
 
The phenotype and functional profile of effector T cells in cancer are dramatically 
altered by the tumor microenvironment. Three different processes of T cell 
impairment can be distinguished on the basis of functional state of the cell: T cell 
anergy, exhaustion and senescence.  
T cell anergy is generally described as the induced hyporesponsive state with low 
IL-2 production and cell cycle arrest at the G1/S phase, to which naïve T cells fall 
upon low co-stimulatory and/or high co-inhibitory stimulation. Under 
physiological conditions T cell anergy functions to induce tolerance in the 
periphery and protects the host from developing autoimmune disease, however 
there are evidences that this mechanism plays an important role also in the context 
of tumor microenvironment (reviewed in 153). One of the mechanisms is due to the 
expression of B7-family members by tumor cells and immune cells, accompanied 
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by a low or absent expression of B7-1 and B7-2, thus indicating a poor co-
stimulatory and high co-inhibitory signals. However, cellular and molecular 
mechanisms controlling T cell anergy are still insufficiently understood. Early 
growth response gene 2 (Egr2) may be a central transcription factor that regulates 
T cell anergic state 154 and it has been suggested that the anergy program is 
initiated by improper mTOR and Ras/MAPK signalling, a pathway that lies 
directly downstream of TCR/CD28 engagement 155,156. Moreover, the E3 
ubiquiting ligase family can affect PI3K, mTOR and Ras/MAPK pathways 
actively maintaining anergy  and epigenetic factors such as IKAROS and Sirt1 are 
involved in histone modifications that promote T cell anergy (reviewed in 153). 
Thus, anergy is the combined result of negative regulation of TCR-coupled signal 
transduction and of a program of active transcriptional silencing reinforced 
through epigenetic mechanisms 157. The incomplete knowledge of the molecular 
mechanisms involved in the process has hindered also the definition of specific 
markers for anergic T cells, that are thus difficult to characterize. 
T cell exhaustion occurs when T cells are chronically activated at sites of chronic 
inflammation, such as cancer, autoimmunity and chronic infection. One of main 
features of T cell exhaustion, is the loss of function of CD8+ and CD4+ T cells, 
that gradually leads to dysfunctional T cells. Exhausted T cells are described as 
effector T cells with decreased cytokine expression, decreased effector 
functionality and resistant to reactivation 158. Exhausted T cells are marked by the 
expression of inhibitory receptors that have a key role in this process. Initial 
mouse studies have proposed that B7-H1/PD-1 signalling pathway mediates CD8+ 
T cell functional exhaustion in the context of chronic infection and PD-1 was 
proposed as marker for exhausted T cells 159. The observation that tumoral cells 
and APCs in tumor microenvironment express B7-H1 and that TILs express PD-1 
has revealed that the axis B7-H1/PD-1 can be involved in T cell exhaustion also in 
tumor context. The detailed molecular mechanism of T cell exhaustion is still 
incompletely defined but it was suggested that recruitment of protein tyrosine 
phosphatases, such as SHP-1 and SHP-2, to the immunoreceptor tyrosine-based 
switch motif (ITSM) within the PD-1 cytoplasmic tail inhibits signalling events 
downstream of the TCR 160. Other studies done with the aim to better characterize 
PD-1+ T lymphocytes have revealed that these cells express on their surface T cell 
immunoglobulin and mucin-domain-containing molecule-3 (Tim-3), lymphocyte-
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activation gene (LAG)-3, and the Band T-cell lymphocyte attenuator (BTLA, 
CD272), 2B4 (CD244), CTLA-4, CD160 (reviewed in 153). However, it is still 
controversial if the co-expression of these inhibitory molecules is functionally 
important to determine T cell functional state (reviewed in 153).  
Another mechanism of T cell functional impairment is T cell senescence. 
Senescent T cells are characterized by telomere shortenings, phenotypic change 
(loss of CD28 expression) and cell cycle arrest 161. Senescent T cells manifest 
defective killing abilities and the development of negative regulatory functions 
162
. Senescence is naturally associated with physiological ageing, however it was 
demonstrated that it can be induced in vitro by tumor cells 163. Phenotypically, 
senescent CD28dim/- CD8+ T cells are observed in patients with lung cancer 164 and 
head and neck cancer 165. In addition to low expression of CD28, high expression 
of Tim-3, CD57, killer cell lectin-like receptor subfamily G, member 1 (KLRG-1) 
are thought to be associated with T cell senescence (reviewed in 153). Concerning 
the molecular mechanisms, it is known that Tim-3 interacts with its ligand 
Galectin-9 that, in turn, induces intracellular calcium flux, aggregation and death 
of Th1 cells 166. An involvement of human leukocyte antigen (HLA)-B-associated 
transcript 3 (BAT3) was also postulated,  but how the interaction between TIM-3 
and Bat3 leads to T cell senescence remains to be elucidated 167. 
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2. AIM OF THE PROJECT 
 
Among the mechanisms carried out by tumor cells to evade immune response, a 
key role is played by the expansion of MDSCs, an heterogeneous population of 
immature myeloid cells able to inhibit both innate and adaptive immunity in 
mouse tumor models and in cancer patients. Of note, it was demonstrated that 
MDSC’s levels correlate with tumor burden and are associated to poor efficacy of 
immunotherapy strategies in cancer patients. However, the molecular mechanisms 
involved in MDSC activity are still poorly understood.  
We previously demonstrated that MDSCs can be derived in vitro by treating fresh 
BM cells with the cytokines G-CSF and GM-CSF and we observed that the 
activation state of T lymphocytes is able to influence the phenotype and 
proliferation of MDSCs, thus suggesting the existence of a crosstalk between 
MDSCs and T cells. We therefore evaluated the molecules potentially involved in 
the interaction with activated T cells.  
 
In particular, we focused our attention on the role of IL-10, a cytokine known to 
have immunosuppressive properties, studying if this cytokine is increased in the 
process of immunosuppression mediated by MDSC.  
 
We also studied the role of the transcription factor STAT3, since it can be 
activated by G-CSF, GM-CSF and IL-10 and it is involved in MDSC expansion. 
  
Since immunosuppression mediated by MDSCs is dependent on cell-to cell 
contact with activated T cells, we investigated the expression on MDSCs and on T 
cells of ligands and receptors that can mediate inhibitory pathways leading to an 
impairment of T cell function.    
 
Finally, we started to evaluate the findings obtained with our in vitro model of 
immune suppression, by analysing the presence of MDSCs and T lymphocytes in 
liver metastases from colorectal cancer patients to determine if the molecular 
mechanisms discovered in vitro are active also in vivo.  
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3. MATERIALS AND METHODS 
3.1 BM samples   
Fresh BM aspirate samples were received from the Department of Woman and 
Child Health, University of Padua. These samples were obtained from patients 
with suspected leukemia or lymphomas, patients with lymphatic leukemia after 78 
days without recurrences, and patients with lymphatic leukemia after BM 
transplantation as a part of the diagnostic follow-up. For this study only samples 
with normal cytological characteristics were used. The project was approved by 
Ethics Committee and all patients gave their informed consent.  
 
3.2 BM-MDSC generation and separation of BM-MDSC subsets 
Red blood cells present in BM aspirates were lysed with a hypotonic solution 
containing NH4Cl 0.15 M (Sigma-Aldrich), KHCO3 0,01 mM (Analytical Carlo 
Erba), Ethylenediaminetetraacetic acid (EDTA) 0,1 mM (Sigma-Aldrich) at room 
temperature (RT) for 5 minutes. The obtained cells were washed, counted and 
labeled with immunomagnetic beads anti-CD3ε, CD19 and CD56 (Miltenyi 
Biotec) in order to deplete T, B and NK lymphocytes, respectively. 
Immunomagnetic beads were added to the cell pellet in a quantity of 20µl/107 
cells, in a total volume of 100µl/107 cells of cold Buffer Sorting, composed of 
phosphate buffered saline (PBS) (LONZA) additioned with 0, 5% Bovine Serum 
Albumin (BSA, SIGMA) and 2mM EDTA (Sigma-Aldrich). Cells were then 
incubated for 15 minutes at 4°C, stirring a few times. Cells were then washed and 
subjected to immunomagnetic negative separation with LD column (Miltenyi 
Biotec) following manufacturer’s instructions. Negative fraction was subsequently 
washed and resuspended in Iscove’s Modified Dulbecco’s Medium (IMDM,  
GIBCO, Life Technologies) supplemented with 10% Fetal Bovine Serum (FBS, 
GIBCO, Life Technologies), 0.01M HEPES (LONZA), 10 U/ml 
penicillin/streptomycin (LONZA), Arginine 0,55 mM (Sigma-Aldrich), 
Asparagine 0,24 mM (Sigma-Aldrich) and Glutamine 1,5 mM (Sigma-Aldrich) 
and β-mercaptoethanol (Sigma-Aldrich). Cell purity was checked by FACS 
analysis on forward scatter/side scatter parameters with a FACSCalibur cytometer 
(BD Biosciences). 
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Lymphocyte-depleted BM cells were cultured in 24-multiwell plates at a 
concentration of 1x106 cells/ml with 40 ng/mL of recombinant human (rh) G-CSF 
(Miltenyi Biotech) and rh-GM-CSF (Miltenyi Biotech) for 4 days at 37°C, 8% 
CO2, in order to expand BM-MDSCs, following the protocol previously 
published80. After the treatment with rh G-CSF+GM-CSF, BM-MDSCs  were 
harvested, washed and depleted of the mature CD11b+ fraction  with 
immunomagnetic anti–human CD11b beads (Miltenyi Biotec), using LD columns 
(Miltenyi Biotech). The purity of CD11blow/- (iBM-MDSCs) and of  CD11b+ 
(mBM-MDSCs) cells obtained from BM-MDSCs was checked by staining both 
fractions with anti-CD16 FITC (BD Pharmingen) and anti-CD11b PE (Beckman 
Coulter) antibodies.  
 
3.3 Proliferation assay 
Peripheral Blood Mononuclear cells (PBMCs) were isolated from peripheral 
blood of healthy donors by density gradient centrifugation on Ficoll-Paque PLUS 
(GE Healthcare-Amersham). Peripheral blood was diluted 1:3 in PBS, stratified 
on Ficoll-Paque PLUS and centrifuged 30 minutes at 1800 rpm at 20°C. After 
centrifugation, PBMCs were aspirated, washed 3 times with PBS 1% human 
serum type AB (HS) (LONZA), and stored in liquid nitrogen. At the moment of 
the experiment,   PBMCs were thawed and stained with CellTrace Violet Cell 
Proliferation Kit (Molecular Probes). For the staining, PBMCs were resuspended 
in PBS at 2x107 cells/ml and incubated with CellTrace at a final concentration of 1 
µM for 5 minutes at 37°C. Then FBS was added at a dilution of 1:5 of the total 
volume. Cells were washed and then plated for 30 minutes at 37°C, 8% CO2 in a 
24 well plate.  CellTrace-labelled PBMCs were then washed again and plated in a 
96-well flat-bottom plate previously coated with 0,5 µg/ml anti-CD3; 5 µg/ml 
soluble anti-CD28 (BioLegend) were added to the culture as co-stimulus. i-BM-
MDSCs and mBM-MDSCs were co-cultured with stimulated PBMCs at 1:1 ratio 
for 4 days at 37°C and 5% CO2 in arginine-free Roswell Park Memorial Institute 
medium (RPMI, Biological Industries), supplemented with 150µM arginine, 10% 
FBS (Biowhittaker), 10 U/ml penicillin/streptomycin, and HEPES. Anti-IL-10 
(Biolegend), anti-PD-1 (Miltenyi Biotech) and anti-B7-H1 (eBioscience) blocking 
antibodies were added to the co-cultures of activated T cells and iBM-MDSCs in 
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a concentration of respectively 10 µg/ml, 1 µg/ml and 1 µg/ml. Stattic, the 
inhibitor of the Tyr-705 phosphorylation of STAT3, was used at the concentration 
of 5 µM to pre-treat iBM-MDSCs for 30 minutes at room temperature before 
adding them to the co-culture with activated T cells.  
At the end of the cultures, cells were harvested and stained with anti-CD3 PECy7 
(Beckman Coulter) antibody. Before acquisition, cell suspensions were transferred 
into TruCountTM  tubes (BD Biosciences), in order to determine the absolute cell 
number of CD3+ cells in the samples.  Data acquisitions were performed on LSRII 
flow cytometer (BD Bioscience). Proliferation of CD3+ CellTrace+ T cells  was 
evaluated both qualitatively and quantitatively, by assessing the signal of 
CellTrace on CD3+ cells.  The extent of T cell proliferation was quantified, 
analyzing the percentage of proliferating cells from generation 3 to generation 10, 
assumed to be 100% without BM-MDSCs. In addition, it was evaluated the ratio 
between the absolute number of CD3+CellTrace+ cells co-cultured with BM-
MDSCs and the number of the same cells stimulated in the absence of BM-
MDSCs.  
 
3.4 Flow cytometric analysis of BM-MDSCs and activated T cells 
The phenotype of BM-MDSCs and activated T cells alone or in co-culture was 
evaluated by flow cytometry using anti-B7-H1 PE  (eBioscience), anti-B7-H2 PE 
(BioLegend), anti-B7-H3 PE (BioLegend), anti-CD33 APC (BD Bioscience), 
anti-CD3 PECy7 (Beckman Coulter), anti-CD8 APC-H7 (BD Bioscience), anti-
LAG3 FITC (AdipoGen), anti-PD1 PE (Miltenyi Biotec). For the staining, 
approximately 105 cells were washed and incubated with Fc Receptor (FcR) 
Blocking Reagent (Miltenyi Biotec) for 15 minutes and then labelled with 
monoclonal antibodies (mAbs) for 20 minutes on ice. Cells were then washed and 
resuspended in 250 µl of cold HCF(137 mM  NaCl, 5 mM KCl, 0.3 mM 
Na2HPO4, 0.7 mM KH2PO4, 0.4 mM MgSO4, 0.3 mM MgCl2, 5 mM glucose, 4 
mM NaHCO3, 1mM EDTA) supplemented with 1% FBS  and then analysed on 
either a FACSCalibur (BD Bioscience) or LSRII cytometer (BD Bioscience). To 
determine the percentage of apoptotic and early apoptotic cells, after the staining 
with anti-CD3 PECy7, cells were washed with HCF, resuspended in 100 µl of 
Annexin V binding buffer (BioLegend) and incubated with Annexin V Alexa 647 
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(BioLegend) plus 7AAD (eBioscience) for 15 minutes at RT. Samples were then 
supplemented with additional 200 µl of Annexin V binding buffer and  
immediately analysed by FACSCalibur. Data were elaborated using FlowJo 
software (Tree Star Inc.) version 7.2.5 
 
3.5 Analysis of IL-10 production 
The supernatants of cell cultures of BM-MDSCs and activated T cells were 
harvested after 4 days of culture, centrifuged at 2000 rpm  for 6 minutes at 4°C 
and stored at -80°C. The concentration of IL-10 was determined by ELISA 
Ready-SET-Go (eBioscience), following manufacturer’s instruction. Briefly, 96-
well plates were coated over-night with 100 µl/well of anti-IL10 capture antibody, 
then washed 3 times with a washing buffer composed of  PBS 0,05% Tween20 
(Sigma-Aldrich) and incubated for 1 hour with a saturating solution. After 3 
washes, properly diluted supernatants and IL-10 standards were added to the plate 
and incubated for 2 hours at RT. The plate was then washed 3 times and 100 
µl/well of anti-IL10 biotinylated antibody were added for 1 hour. Other 3 washes 
were performed and then wells were filled with 100 µl of avidin-horseradish 
peroxidise (HRP) and plate was incubated for 30 minutes at RT. After 3 washes, 
100 µl/well of HRP substrate were added. The enzymatic activity of HRP was 
stopped after 15 minutes by adding sulphuric acid. The plate was then analysed by 
Victor X4 plate reader (Perkin Elmer).    
To determine which cells were responsible of IL10 production, we performed IL-
10 secretion assay (Miltenyi Biotech) on activated T cells alone or in the presence 
of iBM-MDSCs. PBMCs cultured with or without 100 ng/ml of LPS for 14 hours 
were used as positive and negative control, respectively. Cells were harvested, 
washed with a buffer containing PBS 0.5% BSA, 2mM EDTA and incubated 5 
minutes on ice in a mixture of catch reagent and FcR blocking solution. A large 
amount of warm RPMI 3% HS was added to dilute cells that were incubated for 
45 minutes at 37°C  stirring the tubes  every 5 minutes to prevent contact of cells 
which would lead to cross contamination with cytokines. At the end of incubation, 
the cells were washed twice by filling up the tubes with cold buffer, and 
centrifuging them at 1700 rpm for 10 minutes at 4°C. LPS-stimulated or 
unstimulated PBMCs were subsequently incubated with IL-10 Detection 
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Antibody PE, anti-CD14 APC (BioLegend), anti-CD3 PECy7 (Beckman Coulter) 
for 10 minutes on ice, while MDSC/T cell co-culture were labelled with anti-IL-
10 Detection Antibody PE, anti-CD33 APC (BD Bioscience),  anti-CD3 PECy7 
(Beckman Coulter). Cells were washed and immediately analysed by LSRII flow 
cytometer.  
 
3.6 Protein extraction and Western Blot analysis 
After immunomagnetic sorting, iBM-MDSCs and mBM-MDSC fractions were 
stored for Western Blot analysis. About 106 cells were washed with PBS, 
resuspended in 500µl of PBS plus 1% Protease Inhibitor Cocktail (Calbiochem) 
and centrifuged for 6 minutes, at 4°C, 2000 rpm. The supernatant was discarded 
and pellet was stored at -80°C. 
Nuclear and cytoplasmic protein fractions were obtained using NE-PER Nuclear 
and Cytoplasmic Extraction Reagents (Thermo Scientific). The frozen pellet was 
thawed in the presence of 50 µl of ice-cold CERI reagent, supplemented with 1:10 
Protease Inhibitor Cocktail, 50 mM NaF, 1 mM Na3VO4, 5mM EDTA pH 8,00, 2 
mM PMSF (SIGMA),  vortexed vigorously to resuspend the pellet and incubated 
on ice for 10 minutes. Then 2,5 µl of CERII reagent were added to the sample  
which was vortexed and incubated on ice for one minute. After centrifugation, the 
supernatant, containing the cytoplasmic protein fraction, was withdrawn and the 
remaining pellet was then resuspended in 12 µl of ice-cold NER reagent, 
supplemented with the same protease inhibitors of CERI. The sample was 
incubated on ice for 40 minutes, vortexing every 10 minutes. After centrifugation, 
the supernatant, containing the nuclear protein fraction, was withdrawn.  
Protein fractions were quantified with Bradford Method. Calibration curve was 
created using different quantities of BSA (Ultrapure BSA Non-Acetylated, 
Applied Biosystem). Absorbance was determined using a DU530 UV/Vis 
spectrophotometer (Beckman) at a wave length of 595 nm.  
To evaluate P-STAT3 and STAT3 protein expression, nuclear and cytoplasmic 
protein extracts were separated on a 10% sodium dodecyl sulphate (SDS) 
polyacrylamide gel in denaturing conditions. Electrophoresis was performed with 
a XCell II™ SureLock  (Life Technologies) at a voltage of  90 V until the samples 
entered the resolving gel and subsequently at 120 V. Proteins were transferred on 
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a Polyvinylidene fluoride (PVDF) membrane (Millipore) by electric transfer, 
carried out with a Mini Trans-Blot® cell (BioRad) at 350 mA for 2 hours. 
Membrane was stained with Ponceau Red dye (Fluka) to test protein transfer 
efficiency, then briefly washed with PBS supplemented with 0,05% Tween 20 
(SIGMA) and saturated with PBS, 0,05% Tween 20, 5% BSA (SIGMA Aldrich) 
for 1 hour at room temperature. After a rapid wash, the membrane was hybridized 
with rabbit anti-human STAT3 mAb (Cell Signalling Technology) and anti-P-
STAT3 (Tyr705) mAb (Cell Signalling Technology) diluted 1:1000 in PBS 0,05% 
Tween 20, 5% BSA shaking overnight at 4°C. After three more washes of 10 
minutes, the membrane was hybridized with the secondary HRP-conjugated 
donkey anti-rabbit IgG antibody (NA934V, GE Healthcare) diluted 1:5000 in PBS 
with 0,05% Tween 20 and 5% BSA, shaking for 1h at 4°C. After 3 more washes, 
chemioluminescence was developed incubating the membrane with SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific) reagent for 5 minutes 
in the dark and then the signal was acquired with ChemiDoc XRS (Bio-Rad). 
Subsequently, hybridization with mouse anti-human Nucleoporin p62  mAb (BD 
Transduction Laboratories) and mouse anti-human β-actin  mAb (Santa Cruz 
Biotecnology Inc.), both diluted in PBS, 0,05% Tween 20, 5% BSA, was 
performed. For these two antibodies a secondary HRP-conjugated, sheep anti-
mouse IgG antibody (GE Healthcare) was used, diluted 1:5000 in PBS, 0,05% 
Tween 20, 5% BSA. 
 
3.7 Intracellular staining for P-STAT3 
iBM-MDSCs before and after 20 hours of co-culture with T cells were analyzed 
by flow cytometry for the expression of P-STAT3. The staining was performed 
also after the addition in the co-culture of anti-IL10 blocking antibody and after 
the pre-treatment of  iBM-MDSCs with Stattic, as previously described. 2x105 
cells were washed with staining buffer, composed of  PBS + 4% FBS , then 50 µl 
of PBS with 1% formaldehyde were added and tubes were incubated for 10 
minutes at 37°C. After 2 washes with staining buffer, 450 µl of cold methanol 
were added and cells were fixed for 15 minutes at -20°C. After 2 more washes, 
cells were incubated for 30 minutes at RT with 50 µl of rabbit anti-human P-
STAT3 (Tyr705)  mAb (Cell Signalling Technology) diluted 1:100 in PBS + 4% 
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FBS. Next, cells were washed and incubated for 30 minutes at RT with 50 µl of 
DyLight488-donkey anti-rabbit IgG antibody (BioLegend) diluted 1:700 in PBS + 
4% FBS. After a wash, cells were resuspended in 250 µl of staining buffer. As 
positive control for the staining, HepG2 (liver hepatocellular) cells treated with rh 
IL-6 (PeproTech) were fixed and permeabilized as previously described and 
frozen at -20°C in RPMI medium containing 10% glycerol and 20% FBS. For 
each experimental run, the positive control was stained with mAb together with 
the samples. For all samples data acquisition was performed on LSRII flow 
cytometer.  
 
3.8 FACS sorting to separate B7-H1+ and B7-H1- subsets  
iBM-MDSCs and CellTrace-labelled PBMCs stimulated with anti-CD3/CD28 
were harvested after 20 hours of co-culture and collected in polypropylene tubes 
previously rinsed with FBS. Cells were washed with a sorting buffer composed of 
HCF 2% FBS, 0.5 mM EDTA (SIGMA), 1% PenStrep (LONZA), and then 
incubated on ice for 15 minutes with FcR blocking. Anti-B7-H1 PE (eBioscience) 
mAb was added and cells were incubated on ice for 20 minutes. After a wash, 
cells were resuspended in 1 ml of sorting buffer and B7-H1+ and B7-H1- subsets, 
within CellTrace- cells, were separated by FACS ARIA (BD Bioscience). On both 
subsets, an intracellular staining for P-STAT3 was performed as previously 
described. 
 
3.9 Analysis of STAT3 target genes by TRANSFAC database 
Genes already validated as targets of STAT3 in Homo sapiens were retrieved by 
means of the TRANSFAC Professional database (release 2013.3), containing 
published data on eukaryotic transcription factors, their experimentally-proven 
binding sites and regulated genes. Both direct targets of STAT3 and of complexes 
in which STAT3 takes part were considered for the analysis. 
3.10 Colon cancer patients cohort 
Biopsies from liver metastases of stage IV colorectal cancer patients were 
received from the biobank of the Department of Surgery, Oncology and 
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Gastroenterology of the University of Padova. The project was approved by 
Ethics Committee and all patients gave their informed consent. 
  
3.11 Enzymatic digestion of biopsies and flow cytometric analysis 
Biopsies were collected in 0.9% NaCl  solution and processed immediately after 
the withdrawal. They were dissected into small pieces and resuspended in an 
enzymatic mix composed of collagenase 1 g/l, (Sigma-Aldrich), hyaluronidase 
100 mg/l (Sigma-Aldrich), DNAse 30 U/ml. The enzymatic digestion was 
performed at 37°C, shaking for 40-60 minutes. At the end of the incubation, the 
remaining aggregates were broken up and cell solution was filtered through a 100 
µm cell strainer. Cells were washed with IMDM supplemented with 10% FBS, 
1% PenStrep, 1% Hepes and, if necessary, red blood cells were lysed as described 
for BM samples. 5 x 105 cells were aliquoted in each tube for flow cytometry 
analysis. Cells were washed with HCF 1% FBS, incubated with FcR blocking 
solution for 15 minutes on ice and then stained with two mix of mAbs, one for 
myeloid cells and one for the characterization of T lymphocytes. The first mix 
contained: Livedead Aqua (Life Technologies), anti-CD45 Vioblue (Miltenyi 
Biotec), anti-CD33 PECy7 (eBioscience), anti-HLA-DR PerCP-Cy5.5 
(BioLegend), Lineage cocktail 1 FITC (BD Bioscience), anti-CD11b Alexa700 
(BD Pharmingen), anti-B7-H1 PE (eBioscience). The second mix contained: 
Livedead  Aqua, anti-CD45 Vioblue, anti-CD33 PECy7, anti-HLA-DR PerCP-
Cy5.5, anti-CD3 ECD (Beckman Coulter), anti-CD8 APC-H7 (BD Bioscience), 
anti-LAG-3 FITC (AdipoGen), anti-PD1 PE (Miltenyi Biotec).  After incubation 
with mAbs, cells were stained with Annexin V Alexa 647 and samples were 
immediately analysed by LSRII flow cytometer. 
 
3.12 Statistical analysis 
Data were analyzed using SigmaPlot (Systat Software). When data distribution 
passed the normality test, Student’s t test was applied, otherwise Mann-Whitney 
U test was performed. The results were considered statistically significant with 
P<0,05. 
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4. RESULTS 
4.1 Role of IL-10 in the immune suppression induced by MDSCs 
expanded in vitro 
We recently demonstrated that the in vitro treatment of freshly isolated BM cells 
with the addition of the cytokines G-CSF and GM-CSF induces the expansion of 
MDSCs from cell precursors present in BM samples, and we named these cells 
BM-MDSCs 80. Further characterization of these cells revealed that BM-MDSCs 
are a heterogeneous immature myeloid cell population and that the 
immunosuppressive activity is retained by the most immature subset (immature 
BM-MDSCs, iBM-MDSCs). This cell population shares the morphology and the 
markers of promyelocytes and is equivalent to MDSCs present in the peripheral 
blood of breast and colorectal cancer patients 103. To understand which molecular 
mechanisms are involved in the immunosuppression mediated by iBM-MDSCs, 
we focused our attention on soluble factors, and in particular on IL-10, a cytokine 
known to have inhibitory effects on the immune system. We therefore performed 
an ELISA essay to test the production of this cytokine on the supernatants of the 
cultures of T cells and i-BM-MDSCs (Figure 1). T cells were labeled with 
CellTrace and cultured in the absence of stimuli or with anti-CD3/CD28 
antibodies for 4 days. Unfractionated BM-MDSCs and iBM-MDSCs were 
cultured alone or in the presence of activated T cells for 4 days. As control, the 
most mature subset isolated from BM-MDSCs (mature BM-MDSC, mBM-
MDSC) was also used. At the end of the culture, IL-10 concentration was 
quantified on the supernatants. As shown in figure 1,  the highest level of IL-10 
release was reached when activated T cells were cultured in the presence of iBM-
MDSCs, while cultures between activated T lymphocytes and unfractionated BM-
MDSCs or the mBM-MDSC had lower levels of IL-10 production. Activated T 
cells alone produced IL-10, but the concentration increased more than two fold in 
the presence of iBM-MDSCs. A negligible concentration of IL-10 was detected in 
the supernatants of resting T cells and of BM-MDSC subsets cultured alone. 
These data indicate that the co-culture between activated T lymphocytes and 
immunosuppressive cells induces a significant  increase in the release of IL-10, 
although this essay does not allow to discriminate if myeloid or lymphoid cells are 
responsible for IL-10 secretion. 
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Figure 1: IL-10 release is increased in the co-culture between activated T 
cells and iBM-MDSCs. 
ELISA essay performed on the supernatant of cell cultures of CellTrace labelled-
PBMCs stimulated with anti-CD3 and anti-CD28 antibodies for 4 days, alone or 
in the presence of BM-MDSCs, mBM-MDSCs and iBM-MDSCs. Cultures of 
different BM-MDSC subsets alone and of unstimulated PBMCs were performed 
as control (r-T cells= resting T cells, a-T cells= activated T cells). In each 
experiment, IL-10 concentration was normalized on activated T cells and 
expressed as fold change. The histogram shows the mean ± standard error (SE) of 
10 independent experiments. Mann-Whitney U test was applied. 
 
We therefore performed a flow cytometry-based IL-10 secretion assay, that allows 
to identify which cells are secreting the cytokine. We cultured activated T cells 
alone and in the presence of iBM-MDSCs and we checked for IL-10 production 
by T and myeloid cells, by gating respectively on CD3+ and on CD33+ cells 
during the 4 days of culture. Our results demonstrate that activated T cells are 
mainly responsible of IL-10 secretion in the co-culture with iBM-MDSCs, while 
the contribution of myeloid cells is very low (Figure 2A). The percentage of  T 
cells producing IL-10 is increased when activated T lymphocytes are cultured in 
 49
the presence of iBM-MDSCs as compared to activated T cells alone. Concerning 
the kinetics of IL-10 release, we observed that the cytokine is rapidly released 
after one day of culture, and that its secretion increases up to the third day, 
reaching a plateau after 4 days (Figure 2C). At each time point IL-10 release by T 
cells in the presence of iBM-MDSCs was always higher as compared to 
unstimulated T cells cultured in the presence of iBM-MDSCs. Taken together, 
these results indicate that the presence of iBM-MDSCs induces IL-10 production 
by activated T cells and that IL-10 secretion is an early event among the 
molecular mechanisms of MDSC-mediated inhibitory activity.    
 
 
Figure 2: IL-10 is secreted by activated T cells following contact with iBM-MDSCs. 
(A) IL-10 secretion assay was performed on CellTrace-labelled PBMCs stimulated with 
anti-CD3 and anti-CD28 for one day, alone or in the presence of iBM-MDSCs. Cell 
cultures were stained with mAbs anti-CD3 and anti-CD33 in order to discriminate 
between T cells and myeloid cells. Gating of IL-10+ cells was set on the basis of a 
fluorescence minus one (FMO) control. (B) Panel B shows the results of IL-10 secretion 
assay performed on monocytes cultured with or without 100 ng/ml of LPS for 14 hours. 
(C) Kinetics of IL-10 secretion assay in 4 days cell cultures of activated T cells with 
(upper line) or without (lower line) iBM-MDSCs. These results are representative of 3 
independent experiments.  
 
4.2 Role of STAT3 phosphorylation in MDSC-mediated immune 
suppression 
 
Since our results show that iBM-MDSCs increase the release of IL-10 by co-
cultured T cells, we asked which signalling pathways can be activated by this 
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cytokine. We focused our attention on STAT3, a transcription factor known to be 
activated by IL-10 168 and that is involved in immunosuppression 47. To this aim, 
we performed a Western Blot analysis of the nuclear and cytoplasmic fractions of 
proteins extracted from mBM-MDSCs and iBM-MDSCs. We used mAbs directed 
against STAT3 protein and recognizing its phosphorylated form at Tyr705, a 
modification responsible of the translocation of the transcription factor into the 
nucleus. STAT3 consists of two isoforms, named α and β, of respectively 86 and 
79 kDa that differ because the β isoform lacks 55 residues in its C terminal. We 
observed that STAT3 is phosphorylated  on the nuclear and cytoplasmic fractions 
of the iBM-MDSCs (Figure 3, lanes 1) on both isoforms. Only a faint 
phosphorylation could be detected in the mBM-MDSCs in the nuclear fraction, 
but not in the cytoplasmic fraction (Figure 3, lanes 2). No significant differences 
between the two BM-MDSC subsets were detected when considering total STAT3 
expression. In line with the literature, these results demonstrate STAT3 
phosphorylation in the suppressive subset of BM-MDSCs.   
   
 
 
 
Figure 3: P-STA3 is expressed mainly in iBM-MDSCs. 
Western blot analysis of P-STAT3 and STAT3 isoforms’ expression in the 
nuclear (NF, left panel) and cytoplasmic (CF, right panel) protein fractions of 
BM-MDSCs. Nucleoporin 62 (Np62) and β-actin were used as endogenous 
controls respectively for nuclear and cytoplasmic fractions. Molecular weight of 
the proteins was determined on the basis of a chemiluminescent marker (M). 
 
Since these results demonstrate STAT3 activation in iBM-MDSCs, we decided to 
investigate if the phosphorylation of STAT3 in these cells is influenced by the co-
culture with T lymphocytes. To this aim, we optimized a flow cytometry 
intracellular staining to detect if the phosphorylation of STAT3 at Tyr705 changes 
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in different culture conditions. Flow cytometry analysis revealed that among iBM-
MDSCs two cell populations  can be distinguished on the basis of their different 
morphology, one presenting a high side-scatter (SSC) and one with a low SSC. 
These two populations differ in terms of STAT3 phosphorylation, since the 
SSChigh cells are partially phosphorylated, while SSClow cells are completely 
negative (Figure 4).  
 
 
Figure 4: P-STAT3 analysis by flow cytometry on iBM-MDSCs.  
Intracellular staining for P-STAT3 was performed on iBM-MDSCs. Side-scatter 
high (SSChigh) and side-scatter low (SSClow) cells were gated. Black histograms 
show the signal of secondary antibody alone. These results are representative of 4 
independent experiments. 
 
We thus evaluated P-STAT3 mean fluorescence intensity (MFI) in the SSChigh 
subset of iBM-MDSCs before and after 20 hours of culture alone or in the 
presence of either resting or activated T lymphocytes (Figure 5A). The staining of 
T cells with CellTrace allowed us to discriminate myeloid cells (CellTrace-) from 
T lymphocytes (CellTrace+) in the co-culture. ∆MFI was calculated by subtracting 
the MFI of secondary antibody from the MFI of P-STAT3 and then the values 
obtained were normalized on iBM-MDSCs cultured alone. This analysis revealed 
that P-STAT3 expression was up-regulated in myeloid cells when they were 
cultured with activated T cells, while in the presence of resting T lymphocytes this  
phosphorylation decreased, becoming almost negligible when iBM-MDSCs were 
cultured alone (Figure 5A). By flow cytometry we also analyzed the expression of 
P-STAT3 in T cells cultured alone or in the presence of MDSCs (Figure 5B). The 
∆MFI of P-STAT3 was calculated as previously described and then the values 
were normalized on the ∆MFI of activated T cells. Activated T cells expressed P-
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STAT3 but in the presence of iBM-MDSCs the extent of phosphorylation was 
significantly increased. Resting T cells also expressed P-STAT3 but at a low level 
and in the presence of MDSCs significantly increased the level of 
phosphorylation. These results suggest the existence of an interplay between 
activated T cells and MDSCs that leads to the activation of STAT-3 signalling 
pathway in both cell types.  Since it is known that STAT3 activation is driven by 
IL-10 and our results show that the production of IL-10 is increased when iBM-
MDSCs are co-cultured with activated T cells, we tested if a  neutralizing anti-IL-
10 mAb had any effect on the activation of STAT3. We therefore added the anti-
IL-10 blocking Ab at the beginning of the co-culture between iBM-MDSCs and 
activated T cells, and we noticed that its presence caused a decrease of STAT3 
phosphorylation on both myeloid cells (Figure 5A) and activated T cells (Figure 
5B), thus confirming that IL-10 is involved in STAT3 activation.  
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Figure 5: Analysis of P-STAT3 expression in iBM-MDSCs and activated T 
cells.  
Intracellular staining for P-STAT3 was performed on iBM-MDSCs and T cells in 
different culture conditions.  iBM-MDSCs were cultured for 20 hours in the 
presence of resting (r-T cells) or anti-CD3/anti-CD28 activated T cells (a-T cells), 
previously stained with CellTrace. To discriminate between myeloid cells and T 
cells in co-culture, cells were gated respectively on CellTrace- and CellTrace+ 
cells and the difference in mean fluorescence intensity (∆MFI) of P-STAT3 was 
evaluated by subtracting the MFI of secondary antibody to that of P-STAT3 
antibody. Values obtained were then normalized on the ∆MFI of iBM-MDSCs 
cultured alone for 20 hours, when considering myeloid cells (A), and on the ∆MFI 
of activated T cells, when evaluating P-STAT3 expression on T lymphocytes. (B) 
Anti-IL-10 mAb (10 µg/ml) was added to the co-culture between a-T cells and 
iBM-MDSCs. The values reported are the mean ± standard error (SE) of 4 
independent experiments. Student’s t test was applied. 
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4.3 Analysis of the expression of B7-family members on iBM-
MDSCs under different experimental conditions 
 
Our results clearly indicate that STAT3 activation is increased both on iBM-
MDSCs and activated T cells when they are co-cultured. STAT3 can induce the 
expression of B7-H1 by binding to its promoter leading to the transcription of the 
gene 169. We thus decided to test the expression of B7-H1 on iBM-MDSCs and 
also to enlarge this study to other members of the B7-family, in particular B7-H2 
and B7-H3. B7-H2 is the ligand of ICOS on T lymphocytes and is known to have 
a co-stimulatory effect, while B7-H3 has an inhibitory effect but its ligand is still 
unknown. We tested the expression of these molecules by flow cytometry on 
iBM-MDSCs before and after 4 days of culture alone or in the presence of either 
resting or activated T cells (Figure 6). We noticed that iBM-MDSCs did not 
express B7-H1, and showed a partial expression of B7-H2 and B7-H3. Upon 
contact with activated T cells, B7-H1 and B7-H3 were highly up-regulated on 
iBM-MDSCs, while in the presence of resting T cells B7-H1 expression was very 
low, and B7-H3 expression was increased but at a lower intensity. The co-
stimulatory molecule B7-H2 had instead a different pattern of expression since it 
was present at low level in iBM-MDSCs, but after culture, either alone or with T 
lymphocytes, its expression decreased even further. Taken together, our results 
suggest that the presence of activated T cells induces on MDSCs the expression of 
surface molecules, such as B7-H1 and B7-H3, that are known to be involved in a 
negative regulation of immune responses.   
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Figure 6: Analysis of the expression of B7 family members on iBM-MDSCs in 
different culture conditions. 
iBM-MDSCs were isolated by immunomagnetic sorting and cultured for 4 days 
alone or in the presence of resting or activated T cells, previously labelled with 
CellTrace. After 4 days, cells were harvested and labelled with CD3 and B7-
H1/B7-H2/B7-H3 mAbs. Myeloid cells were identified by gating on CellTrace-
/CD3- cells and the negative signal (black histogram) was evaluated using a 
fluorescence minus one (FMO) control. The data are representative of 3 
independent experiments. 
 
We next quantified the percentage of B7-H1+ cells in different culture conditions, 
and Figure 7 shows that there is a statistically significant increase in the level of 
B7-H1+ cells among iBM-MDSCs co-cultured with activated T cells, as compared 
to control cultures. Although not statistically significant, we observed a lower 
percentage of B7-H1+ cells in the presence of resting T cells, as compared to 
activated T lymphocytes, thus confirming our previous results.   
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Figure 7: Expression of B7-H1+ cells among iBM-MDSCs in  the presence of 
T cells.  
Staining with anti-B7-H1 mAb was performed on iBM-MDSCs and on the same 
cells cultured for 4 days alone or in the presence of resting or anti-CD3/CD28 
activated T cells, labelled with CellTrace. Myeloid cells were discriminated gating 
on CellTrace-/CD3- cells and the percentage of B7-H1+ cells was obtained using 
an FMO as negative control. The histogram reports the mean ± SE of 4 
independent experiments. Mann-Whitney U test was applied.  
 
We decided to analyse the kinetics of B7-H1 expression during the 4 days of 
culture with activated T cells because we observed that STAT3 phosphorylation is 
an early event occurring after 20 hours of co-culture and from literature we know 
that STAT3 can activate the transcription of B7-H1. We observed that the 
maximum percentage of B7-H1+ cells among MDSCs was reached after the first 
day of culture, then decreased between the first and the second day and was 
maintained almost unchanged until the end of the culture (Figure 8). Moreover, 
we observed that iBM-MDSCs that up-regulate B7-H1 after 20 hours of co-
culture with activated T cells, also present a high SSC, in analogy with the P-
STAT3+ cell subset of iBM-MDSCs. These observations prompted us to 
investigate the link between the expression of these two markers and their 
involvement in the BM-MDSC-mediated immunosuppression.     
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Figure 8: Kinetics of B7-H1 expression on myeloid cells cultured with 
activated T cells. 
Cell surface staining with B7-H1 mAb at different time points of co-culture of 
iBM-MDSCs with CellTrace-labelled T cells activated by anti-CD3/CD28. 
Myeloid cells were defined by gating  CellTrace-/CD3- and then the percentage of 
B7-H1+ cells was evaluated. Results shown are representative of 4 independent 
experiments.  
 
4.4 Evaluation of the relationship between STAT3 activation  and 
B7-H1 expression 
 
To evaluate the link between P-STAT3 and B7-H1, we investigated whether these 
two markers were co-expressed in the same cells. To this aim, we cultured for 20 
hours iBM-MDSCs with activated T cells and then we separated B7-H1+ and B7-
H1- myeloid cells by FACS sorting by gating CellTrace- cells. We performed an 
intracellular staining on sorted cells to detect STAT3 phosphorylation and the 
∆MFI of P-STAT3 was calculated as previously described. As shown in figure 9, 
B7-H1+ cells had a higher intensity of expression of P-STAT3, as compared to 
B7-H1-.  
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Figure 9: P-STAT3 expression in B7-H1+ and B7-H1- cells. 
iBM-MDSCs were cultured with CellTrace-labelled T cells. After 20 hours, B7-
H1+ and B7-H1- myeloid cells were separated by FACS sorting and an 
intracellular staining for P-STAT3 was performed. The ∆MFI for P-STAT3 was 
calculated by subtracting the MFI of the secondary antibody from the MFI of P-
STAT3. Black histograms show the signal of secondary antibody. The results are 
representative of 3 independent experiments.   
 
On the basis of this result, we decided to investigate whether the inhibition of 
STAT3 phosphorylation and therefore of its activation had an effect on the 
expression of B7-H1. To this aim, we analyzed B7-H1 phenotype in iBM-MDSCs 
pretreated with 5 µM Stattic, an inhibitor of STAT3 phosphorylation at Tyr705, 
after 20 hours of co-culture with activated T cells. B7-H1 expression was 
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compared to that of untreated iBM-MDSCs in the same culture conditions. We 
observed that the percentage of cells expressing B7-H1 was significantly reduced 
in the presence of Stattic, thus supporting the notion that STAT3 induces B7-H1 
expression (Figure 10).  
 
 
Figure 10: Stattic reduces the expression of B7-H1 on iBM-MDSCs. 
iBM-MDSCs untreated or pre-treated with 5 µM Stattic for 30 minutes were 
cultured for 20 hours with T cells labelled with CellTrace and activated with anti-
CD3/CD28. The percentage of B7-H1+ cells among CellTrace- myeloid cells was 
quantified as shown in the upper panel. Black histograms represent the FMO 
control for B7-H1. The histograms below  represent the mean ± SE of 3 
independent experiments. Student’s t test was applied.  
 
When we quantified the extent of inhibition of STAT3 phosphorylation induced 
by Stattic, we observed that the treatment caused a marked reduction of P-STAT3 
expression in iBM-MDSCs (Figure 11), although it did not completely abolish P-
STAT3 expression and this could explain why more than 20% of cells still 
 60
expressed B7-H1 after STAT3 inhibition (Figure 10 upper panel). On the other 
hand, the concentration of the inhibitor could not be increased, since higher 
concentrations were toxic on BM cells, causing a marked reduction in cell number 
(data not shown).    
 
Figure 11: Effect of Stattic on P-STAT3 expression on iBM-MDSCs. 
iBM-MDSCs were pre-treated with 5 µM Stattic for 30 minutes and then stained 
for P-STAT3. ∆MFI for P-STAT3 was calculated subtracting the MFI of 
secondary antibody from the MFI of P-STAT3 in both subsets present among 
iBM-MDSCs, characterized by a different morphology (SSChigh and SSClow). 
 
4.5 Inhibition of STAT-3 phosphorylation in iBM-MDSCs restores 
the immune response 
 
We demonstrated that IL-10, STAT3 and B7-H1 are inter-connected in a loop that 
is active in immunosuppressive cells after that they come in contact with activated 
T lymphocytes. We therefore asked if inhibitors of IL-10, STAT3 and B7-H1 
were able to rescue the proliferation of T cells suppressed by MDSCs. To this 
aim, we tested an anti-IL-10 blocking mAb to neutralize IL-10 produced in the co-
culture and anti-B7-H1 plus anti-PD-1 to block the interaction of B7-H1, 
expressed by myeloid cells, with its receptor PD-1 on activated T cells. We chose 
the antibodies’ concentration that was not toxic on activated T cells to avoid side-
effects unrelated to immunosuppression. Instead, Stattic, the inhibitor of STAT3 
phosphorylation at Tyr 705, could not be added directly in the culture because it 
was toxic on T cells even at very low concentration and inhibited their 
proliferation. We therefore chose to pre-treat iBM-MDSCs for 30 minutes and 
 61
then add them to the culture after having washed away the inhibitor. Under this 
condition, we verified that, at least after 24 hours, cell death of Stattic-treated 
iBM-MDSCs was increased only of 3,7%, as compared to untreated cells (data not 
shown). We quantified immunosuppression both in a quantitative manner (Figure 
12, black bars), considering the absolute number of CD3+ lymphocytes, and in a 
qualitative way (Figure 12, grey bars), evaluating the percentage of proliferating T 
cells following the generations of T cell divisions by CellTrace dilution. In both 
types of quantification, the values obtained were then normalized on the activated 
T cells cultured alone, whose proliferation was considered as 100%. As shown in 
figure 12, among the tested molecules, only Stattic was able to rescue the 
proliferation of T cells both quantitatively and qualitatively, although statistical 
significance was reached only when calculating proliferation in a qualitative 
manner. To exclude the possibility that this rescue in T cell proliferation was due 
to a reduction in the percentage of myeloid cells as a consequence of Stattic 
treatment, we evaluated the change in the percentage of myeloid cells and 
observed a non-significant decrease (Figure 13).  Taken together, these results 
indicate that Stattic interferes with the mechanisms that lead to iBM-MDSC-
mediated immunosuppression. Instead, no relevant differences were observed 
when anti-IL-10 and anti-PD-1 with anti-B7-H1 were added to the culture, 
possibly because the inhibition of a single molecule is not sufficient to block the 
immunosuppressive activity of MDSCs that is most likely caused by several 
signalling pathways acting together. The inhibition of the transcription factor 
STAT3 has instead a wider effect in MDSC signaling since it rebounds on all 
STAT3 targets.  
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Figure 12: Proliferation of T cells in the presence of inhibitors for P-STAT3, 
IL-10, PD-1 and B7-H1. 
CellTrace-labelled PBMCs were cultured for 4 days alone and in the presence of 
iBM-MDSCs, pre-treated for 30 minutes with 5 µM Stattic, while mAbs anti-IL-
10 (10 µg/ml), anti-PD-1 and anti-B7-H1 (1 µg/ml) were added at the beginning 
of the culture. After 4 days, cell cultures were  harvested and T cells were stained 
with anti-CD3 antibody. Immunosuppressive activity of iBM-MDSCs was 
evaluated either quantitatively (black bars), considering the absolute number of 
CD3+ T cells, as assessed by TrueCount tubes, and qualitatively, evaluating the 
percentage of proliferating CD3+ T cells (grey bars). For each experiment, the 
values were normalized on the proliferation of activated T cells alone. The 
histograms report the mean of 4 independent experiments ± SE. Student’s t test 
was applied.  
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Figure 13: Effect of Stattic on iBM-MDSCs. 
iBM-MDSCs were pre-treated with 5 uM Stattic for 30 minutes and then cultured 
with CellTrace-labelled T cells activated for 4 days with anti-CD3/CD28. At the 
end of the culture, cells were harvested and stained with anti-CD3 mAb. Myeloid 
cells were identified by gating CD3-/CellTrace- cells. The histogram shows the 
mean ± SE of 4 independent experiments. Student's t test was applied. 
 
4.6 Analysis of STAT3 target genes 
 
To gain insight into the signalling pathways activated by STAT3, we checked for 
human genes already validated as targets of STAT3 by the use of the TRANSFAC 
Professional database (release 2013.3) containing published data on eukaryotic 
transcription factors, their experimentally-proven binding sites and regulated 
genes. Table 1 reports the validated target genes and miRNA of STAT3, of  the 
dimer between two molecules (STAT3:STAT3), or of the STAT3 protein 
phosphorylated at Ser 727 (pS727) or at Tyr 705 (pY705), depending on which of 
these forms was used for the binding site validation. Interestingly, among the 
validated target genes we noticed CD274 (B7-H1), already implicated in our 
results, but also genes such as IL-10 and IL6st (gp130) that can both activate a 
positive feedback on STAT3. Other interesting STAT3 target genes are nitric 
oxide synthase (NOS3), an enzyme catalyzing the production of nitric oxide from 
L-arginine and expressed in granulocytic MDSCs 52, and CDKN1A, a gene that 
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encodes for a potent cyclin-dependent kinase inhibitor, blocking the activity of 
cyclin-CDK2 or –CDK4 complexes and thus functioning as a regulator of cell 
cycle progression at G1. Moreover, among the targets of STAT3 it is reported 
miR-155. In this respect, our group recently evaluated microRNAs differentially 
expressed between sorted ex-vivo promyelocytes versus iBM-MDSCs and 
between iBM-MDSCs before or after contact with activated T cells (Solito et al., 
unpublished). Of note, miR-155 is significantly up-regulated in both comparisons, 
thus suggesting that it has a main role in MDSC-mediated immunosuppression. 
Moreover, C/EBPβ is a known target of miR-155 170, and our group demonstrated 
that this transcription factor has a main role in the immunosuppression mediated 
by BM-MDSCs 80 and that the expression of its isoforms in mice was regulated by 
another miRNA that is miR-142-3p 81.  
    
TF target gene number of validated binding sites  
STAT3 SERPINA1 1 
STAT3 AGT 1 
STAT3 BIRC5 3 
STAT3 CCR5 1 
STAT3 CD274 2 
STAT3 CDKN1A 1 
STAT3 CISH 1 
STAT3 CRP 1 
STAT3 CYP19A1 1 
STAT3 DMBT1 1 
STAT3 FAAH 1 
STAT3 FCGR1C 1 
STAT3 FGG 3 
STAT3 FOS 5 
STAT3 FOXM1 1 
STAT3 HBG1 1 
STAT3 HP 1 
STAT3 ICAM1 1 
STAT3 IFNG 2 
STAT3 IL10 2 
STAT3 IL21 1 
STAT3 IL2RA 1 
STAT3 IL2RG 2 
STAT3 IL6ST 1 
STAT3 IRF1 2 
STAT3 LBP 1 
STAT3 MMP1 1 
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STAT3 MMP7 1 
STAT3 MYC 1 
STAT3 MYD88 2 
STAT3 NOS3 2 
STAT3 OPRM1 1 
STAT3 PHB 1 
STAT3 PIM1 1 
STAT3 PML 1 
STAT3 PRF1 1 
STAT3 REG1A 1 
STAT3 ROR1 2 
STAT3 TP63 1 
STAT3 TRH 1 
STAT3 TWIST1 1 
STAT3 VEGFA 1 
STAT3 VIM 1 
STAT3 VIP 1 
STAT3 CD46 2 
STAT3 MIR155 1 
STAT3 SALL4 4 
STAT3 VEGFC 1 
STAT3:STAT3 FCGR1A 1 
STAT3:STAT3 FOS 2 
STAT3:STAT3 GBP1 1 
STAT3:STAT3 ICAM1 1 
STAT3:STAT3 IL10 1 
STAT3:STAT3 IRF1 2 
STAT3 (pS727) CRP 1 
STAT3(pS727) FOS 1 
STAT3(pY705) AGT 3 
STAT3(pY705) ICAM1 1 
STAT3(pY705) IRF1 1 
STAT3(pY705) OAS1 1 
STAT3(pY705) FOS 1 
STAT3(pY705) ROR1 2 
STAT3(p) MUC4 1 
 
Table 1: Validated targets of STAT3 in Homo sapiens. 
Validated target genes of STAT3 in Homo sapiens as reported in TRANSFAC 
database. The first column reports different forms of STAT3 transcription factor 
(TF) .   
 
 
 
 66
4.7 Analysis of T cell-suppression induced by iBM-MDSCs 
From literature it is still not clear the fate of suppressed T cells. We therefore 
investigated whether iBM-MDSCs could induce apoptosis on T cells by the use of 
the two markers 7AAD and Annexin, that allow to discriminate between apoptotic 
(7AAD+/Annexin+ cells), early apoptotic (7AAD-/Annexin+) and live (7AAD-
/Annexin-) cells (gating strategy showed in figure 14, upper panel). We compared 
the percentage of these 3 cell subsets in activated T cells maintained in cell culture 
with or without  iBM-MDSCs. After four days, we observed that the presence of 
MDSCs (Figure 14, grey bars) induced a significant increase in the percentage of 
apoptotic and early apoptotic T cells, as compared to T cells cultured alone (black 
bars) and, accordingly, this result was associated to a reduction in the percentage 
of live T cells. However, the percentage of live T cells still accounted for the 
majority of the cells, so we hypothesized that other mechanisms of T cell function 
impairment could be involved.  
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Figure 14: Analysis of apoptosis induction on T cells cultured with iBM-
MDSCs 
CellTrace-labelled PBMCs were cultured alone or in the presence of iBM-MDSCs 
for 4 days. Cultures were then harvested and cells were stained with anti-CD3, 
Annexin V and 7AAD, to discriminate among apoptotic, early apoptotic and live 
T lymphocytes. Gating strategy is shown in the upper panel. The histogram below 
shows the mean ± SE of 8 independent experiments. Black bars refer to activated 
T cells alone, grey bars to activated T cells in the presence of iBM-MDSCs. 
 
4.8 MDSCs induce markers of cell exhaustion on T cells 
We hypothesized that T cell exhaustion could be a mechanism of immune 
suppression induced by MDSCs. One of main features of T cell exhaustion, is the 
loss of function of CD8+ and CD4+ T cells, that gradually leads to dysfunctional T 
cells. Exhausted T cells are marked by the expression of inhibitory receptors that 
have a key role in this process. One of the best characterized pathway of 
exhaustion is represented by PD-1 and its ligand PD-L1 (also known as B7-H1) 
that has a critical role for CD8 T cell exhaustion in chronically infected mice 171. 
In addition to PD-1, other cell surface inhibitory receptors regulate T cell 
exhaustion. Among them LAG-3, a CD4-related protein expressed on CD4+ and 
CD8+ T cells, negatively regulates T-cell expansion. 
Since our results demonstrated that B7-H1 expression was up-regulated on iBM-
MDSCs following culture with activated T cells, we tested the expression of PD-1 
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on T cell subsets of resting or activated T cells in the presence or absence of iBM-
MDSC. This experiment showed that PD-1 was expressed at low level in resting T 
cells while cell activation caused a high increase in its expression (Figure 15). The 
addition in the culture of mBM-MDSCs did not change significantly the 
expression of PD-1 on activated T cells, as compared to activated T lymphocytes 
cultured alone. Instead, the presence of iBM-MDSCs caused a significant increase 
of PD-1 expression in CD8+ T cells (Figure 15). These results show that PD-1 
expression is mainly driven by T cell activation, although contact with iBM-
MDSC can further up-regulate its expression mainly on CD8+ T cells. 
 
.  
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Figure 15: Evaluation of PD-1 expression in T cell subsets. 
CellTrace-labelled PBMCs were cultured for 4 days alone or in the presence of 
mBM-MDSCs and iBM-MDSCs. Anti-CD3/CD28 antibodies were used to 
activate T cells. At the end of the culture, cells were harvested and stained with 
anti-CD3, anti-CD8 and anti-PD-1 and analyzed gating on CD3+/CellTrace+ cells 
(CD3), CD3+/Celltrace+/CD8- cells (CD4) and on CD3+/CellTrace+/CD8+ cells 
(CD8). The upper histogram shows the percentage of PD-1+ cells in the three 
subsets of T lymphocytes, while the lower graph reports the MFI of PD-1 
calculated in the same cells. The values reported are the mean ± SE of three 
independent experiments. Student’s t test was applied.   
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We next evaluated the expression of LAG-3, another marker of T cell exhaustion. 
This analysis was performed as previously described for PD-1 and in this case T 
cell activation induced only a slight up-regulation of this marker, while a 
significant intensity was reached with iBM-MDSCs (Figure 16) and we observed 
that the strongest increase both of the percentage and in the MFI of LAG-3+ cells 
was induced in  CD8+ T cells. The addition of mBM-MDSCs caused only a slight 
increase of CD8+ /LAG-3+ cells, but had no effect on the other two T cell subsets, 
as compared to activated T cells alone (Figure 16, upper histogram).  No 
statistically significant differences were observed between activated T cells alone 
and in the presence of mBM-MDSCs when considering the MFI of LAG-3+ cells. 
 Overall our results indicate that the expression of the markers LAG-3 and PD-1 
on T cells suppressed by MDSCs is consistent with the phenotype of exhausted T 
cells. 
Interestingly, it has been reported that LAG-3 is a natural ligand for MHC class II 
172
 and that it is a negative co-stimulatory receptor 173. Moreover, recent 
preclinical studies documented a role for LAG-3 in CD8 T cell exhaustion 171. We 
recently demonstrated that HLA-DR expression is increased in iBM-MDSCs co-
cultured with activated T cells 103. Since both LAG3 and HLA-DR expression are 
increased respectively in T lymphocytes and iBM-MDSCs when they are co-
cultured, we speculate that the interaction between these two molecules may 
mediate the inhibitory signalling that leads to immunosuppression.  
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Figure 16: Evaluation of LAG-3 expression in T cell subsets. 
CellTrace-labeled PBMCs were cultured for 4 days alone or in the presence of 
mBM-MDSCs and iBM-MDSCs. Anti-CD3/CD28 antibodies were used to 
activate T cells. At the end of the culture, cells were harvested and stained with 
anti-CD3, anti-CD8 and anti-LAG-3 and analyzed gating on CD3+/CellTrace+ 
cells (CD3), CD3+/Celltrace+/CD8- cells (CD4) and on CD3+/CellTrace+/CD8+ 
cells (CD8). The upper histogram shows the percentage of LAG-3+ cells in the 
three subsets of T lymphocytes, while the lower graph reports the MFI of LAG-3 
calculated in LAG-3+ cells. The values reported are the mean ± SE of three 
independent experiments. Student’s t test was applied.  
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4.9 Analysis of myeloid cells present in liver metastases from 
colorectal cancer patients 
Thus far we have demonstrated that activated T cells induce the activation of 
signalling pathways in suppressive iBM-MDSCs. This result led us to hypothesize 
that normal promyelocytes, present in the bone marrow, can be primed with 
tumor-derived factors to acquire a suppressive phenotype and become MDSCs. 
We believe that these cells are equivalent to the MDSCs found in the blood stream 
and we name these cells “unprimed MDSCs” as they lack the markers of MDSCs 
found after contact with activated T cells, which, instead, we call “effector 
MDSCs”, since they activate their full suppressive ability. Our hypothesis relies 
on the fact that MDSCs are harmless when in contact with resting T cells, but 
acquire a suppressive phenotype only when required, and that this change in 
functional activity is driven by the activation state of the T cells. To verify if the 
mechanisms that we found to be active in vitro are the same driving 
immunosuppression in vivo, we studied myeloid and lymphoid cells present in 
liver metastases of colorectal cancer patients, since at this site “effector MDSCs” 
might be present. As we previously demonstrated that in vitro-derived MDSCs are 
equivalent to Lineage (Lin)-/HLA-DR-/CD33+/CD11b+ MDSCs expanded in 
peripheral blood of stage IV colorectal cancer patients 103, we used this 
combination of markers to study myeloid cells in liver metastases from colorectal 
cancer patients. Thus far we could analyze only 3 samples and therefore this is 
only a  preliminary study, whose results cannot be generalized but that may serve 
us to plan future directions in a higher cohort of samples.  We noticed that in all 3 
samples, among live leukocytes, a very small population of Lin-/HLA-DR-/CD33+ 
cells is present and that this subset also expresses B7-H1 (Figure 17). Further 
studies are needed to verify these findings in a higher number of samples and also 
to determine if Lin-/HLA-DR-/CD33+ cells present in liver metastases are 
endowed with suppressive activity and if B7-H1 is implied in the induction of 
immunosuppression. These studies are challenging due to the very low percentage 
of Lin-/HLA-DR-/CD33+ cells present in tumor biopsies, we are therefore 
optimizing FACS sorting conditions in order to sort a sufficient number of cells 
that will be essayed in a functional assay.  
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Figure 17: Analysis of B7-H1 expression in myeloid cells present in liver 
metastases from colorectal cancer patients 
Cell suspension was obtained with enzymatic digestion from liver metastasis of 
colorectal cancer patients.Surface staining was performed and live leukocytes 
were analysed by gating on Livedead-/Annexin-/CD45+ cells, after doublets 
exclusion. B7-H1 expression was analyzed on Lin-/HLA-DR-/CD33+ cells among 
live leukocytes, setting the gate on the basis of FMO, as negative control. The 
dotplots are representative of 3 independent experiments. 
 
4.10 Analysis of PD-1 and LAG-3 expression in T cells infiltrating 
liver metastases from colorectal cancer patients 
Since we demonstrated that T cells in the presence of iBM-MDSCs acquire a 
phenotype consistent with that of exhausted T cells, we studied the expression of 
exhaustion markers in the lymphocytic counterpart present in liver metastases 
from colorectal cancer patients. To this aim, we set up a multicolor flow 
cytometry staining to analyze PD-1 and LAG-3 expression in CD4+ and CD8+ T 
cell subsets. We noticed that PD-1 was expressed on both CD4+ and CD8+ T cells 
(Figure 18, upper panels), while LAG-3 was absent on both T cell subsets 
analyzed (Figure 18, lower panels). Albeit the role of LAG-3 and PD-1 in T cell 
exhaustion has been documented 171, it was recently demonstrated that their 
expression can be modulated also by T cell differentiation and from the degree of 
T cell activation 174. Therefore we are planning to expand this analysis on a larger 
number of biopsies in order to perform other phenotypic and functional studies 
and determine if T cells present in liver metastases of colorectal cancer patients 
are functionally exhausted.  
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Figure 18: Analysis of PD-1 and LAG-3 expression in T cells present in liver 
metastases from colorectal cancer patients. 
Cell suspension was obtained with enzymatic digestion from liver metastases of 
colorectal cancer patients. If necessary, red blood cell lysis was performed. 
Surface staining was performed and live leukocytes were analysed by gating on 
Livedead-/Annexin-/CD45+ cells, after doublets exclusion. PD-1 and LAG-3 
expressions were analysed on CD3+ cells (CD3), on CD3+/CD8- (CD4) cells and 
on CD3+/CD8+ (CD8) cells among live leukocytes, setting the gate on the basis of 
FMO, as negative control (black histogram). The dotplots are representative of 3 
independent experiments.  
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5. DISCUSSION 
 
Increasing evidence shows that myeloid-derived suppressor cells play a key role 
in the inhibition of immune responses of cancer patients and that their expansion 
is correlated to tumor burden and poor OS. Some of the mechanisms involved in 
the immunosuppressive activity of MDSCs have been studied in different tumor 
models, but a clear picture is still lacking. 
 
Our group demonstrated that G-CSF and GM-CSF are growth factors able to 
induce the expansion of immature myeloid cells from bone marrow precursors 
and that these in vitro-derived cells are endowed with immunosuppressive 
activity. The inhibition of T cell proliferation was dependent on cell-to-cell 
contact and C/EBPβ was shown to be a key transcription factor involved in 
immunosuppressive activity. Since MDSCs derived from BM cells are a very 
heterogeneous cell population, a deeper phenotypic and functional 
characterization was performed and revealed that only the most immature subset, 
resembling to promyelocytes, was responsible of the inhibition of T cell 
proliferation. The phenotype and suppressive capability of these cells was 
influenced by the degree of activation of T lymphocytes, in fact the presence of 
mitogen-activated T cells enhanced the immunosuppression mediated by MDSCs 
and maintained their immature phenotype. These results indicated the existence of 
a cross-talk between MDSCs and activated T cells at the basis of 
immunosuppression. 
 
On the basis of these results, we investigated at molecular level potential 
mechanisms involved in the interplay between MDSCs and activated T cells and 
found that a loop involving surface molecules and a soluble factor is set in motion 
when the two cells interact. 
We found that IL-10 is released by activated T cells and this, in turn, lead to the 
activation of STAT3 in both cell types. Interestingly, a similar mechanism was 
reported also for murine macrophages stimulated with CpG interacting with CD4+ 
T cells activated by anti-CD3/CD28 175. Under these conditions the cell-to-cell 
contact led to an increase in IL-10 production in both cell types. Through the use 
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of the STAT3 inhibitor NSC 74859 it was demonstrated that the activation of 
STAT3 in CD4+ T cells was responsible of the production of IL-10 175.  
We demonstrated that in our model, STAT3 activation was sustained by IL-10 
signalling, although a low level of activation was observed also in MDSCs before 
the contact with activated T cells. This was probably due to the fact that MDSCs 
were derived by using the combination of G-CSF and GM-CSF and it is known 
that both cytokines signal through STAT3 105,176. Studies performed in a murine 
model with conditional deletion of STAT3 in the bone marrow proved that 
hematopoietic progenitor cells and myeloid precursors deleted for STAT3 were 
refractory to G-CSF treatment. These studies also demonstrated that STAT3 
directly controls G-CSF-dependent expression of C/EBPβ 177, a transcription 
factor with a crucial role in emergency granulopoiesis and that, as already 
mentioned, is also critically involved in MDSC immunosuppressive activity 80. 
The involvement of STAT3 in MDSC expansion was proved in studies carried out 
with a mouse model with conditional STAT3 gene disruption in myeloid cells that 
reported a significant reduction in granulocytic MDSCs 178. As for the mechanism 
of action, it is known that STAT3 can modulate MDSC expansion by the up-
regulation of the myeloid-related protein S100A9, a member of the large family of 
S100 proteins that forms a dimer with S100A8. The up-regulation of this protein 
in hematopoietic progenitor cells of colon carcinoma-bearing mice was associated 
to the expansion of MDSCs and to the impaired differentiation of DCs 47. 
CD14+/S100A9+ MDSCs were reported to be expanded also in NSCLC patients 
and to suppress T cell proliferation via iNOS, ARG1, IL-10 and the IL-13/IL-4Rα 
pathway 179.  ARG1 was expressed also on CD14+/HLA-DRlow/- MDSCs on 
HNSCC patients and it was demonstrated that STAT3 activation could lead to 
ARG1 expression by binding to its promoter 180. Therefore STAT3 can regulate 
MDSC expansion and activity by activating different signalling pathways.  
 
In this study we also demonstrated that STAT3 phosphorylation leads to the 
expression of B7-H1, a molecule that can negatively regulate immune responses 
by interacting with its receptor PD-1 on lymphocytes. B7-H1 was reported to be 
expressed on MDSCs obtained from ascites and spleens of mice bearing the 1D8 
ovarian carcinoma and caused immunosuppression by interacting with PD-1 on 
Treg cells 149. Another work performed on a mouse model of ret melanoma 
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reported the expression of B7-H1, B7-H3 and B7-H4 on MDSCs and 
demonstrated that the expression of these molecules was dependent on the 
interaction between MDSCs and Treg cells 181.  
We focused our attention on the B7-H1 molecule since it is known that STAT3 
binding sites are present on the promoter of B7-H1 gene169. Moreover, studies 
performed on patients infected with HIV revealed that, during infection, PD-1 is 
up-regulated on monocytes and that the interaction of PD-1 with B7-H1, 
expressed on other cell types, induced IL-10 production that in turn led to CD4+ T 
cell dysfunction 182. Moreover, IL-10 can modulate PD-L1 up-regulation on 
human macrophages during HIV infection 183. To the best of our knowledge, this 
is the first characterization in human MDSCs of a signalling pathway driven by 
IL-10 that, through the activation of STAT3, leads to the expression of B7-H1. A 
similar loop was described for human monocyte-derived DCs differentiated in the 
presence of TLR agonists. These DCs acquired a tolerogenic function that was 
dependent on MAPK-induced IL-6 and IL-10 production, which drives STAT-3 
mediated B7-H1 expression 184,185. We believe that also in MDSCs there is a 
possible  involvement of IL-6 signalling since we have evidence that this cytokine 
is induced in MDSC, (Pinton, unpublished results) 
On the whole these data suggested us that IL-10, STAT3 and B7-H1 were 
interesting targets to inhibit MDSC activity, but when we tested inhibitors for 
these molecules in the culture between activated T cells and MDSCs, only the 
block of STAT3 activation rescued T cell proliferation. Probably, the inhibition of 
IL-10 alone is not sufficient to block MDSC activity because a residual level of 
STAT3 activation is still present in the presence of IL-10 blocking Ab. Also the 
inhibition of B7-H1 interaction with its receptor PD-1 did not rescue T cell 
proliferation, although we believe that these molecules are critically involved in 
immunosuppression. In fact, preliminary results obtained in our laboratory 
demonstrate that, among MDSCs, only the subset expressing B7-H1 is able to 
inhibit T cell proliferation. Moreover, we have evidence that besides the 
triggering of PD-1 by B7-H1, also the binding of the co-inhibitory receptor LAG-
3 to its ligand MHC-II is involved in the interplay between MDSCs and activated 
T cells. Therefore, the inhibition of the axis B7-H1/PD-1 alone is probably not 
sufficient to restore T cell proliferation.  
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It is known that STAT3 controls a vast array of target genes and thus, in order to 
understand if there are other signalling pathways that might be activated by 
STAT3 in MDSCs, we analysed its validated targets. Besides the genes, we found 
one miRNA that is of particular interest for us. In fact, we recently performed a 
miRNA expression analysis, in which we compared MDSCs derived after 
cytokine treatment with ex vivo sorted promyelocytes and also MDSCs sorted 
after contact with activated T cells as compared to MDSCs before contact, and 
under this condition, miR-155 is always significantly up-regulated. This finding is 
in line with a recent work in which a miRNA expression analysis was carried out 
on murine MDSCs derived in vitro from BM cells treated with the cytokines GM-
CSF and IL-6 as compared to ex vivo cells, and they also found that the most up-
regulated miRNA was miR-155, together with miR-21. Moreover, this work 
showed that miR-155 and miR-21 have a synergistic effect on MDSC induction 
by targeting SHIP-1 and PTEN, respectively, leading to STAT3 activation 186.  
A recent study reported that MDSCs present in breast cancer tissues inhibited T 
cell proliferation and induced apoptosis in T cells in an IDO-dependent manner. 
IDO expression was up-regulated in MDSCs induced from healthy donors 
umbilical cord blood and its expression was dependent on STAT3 activation 187. 
In line with these results, we have preliminary data suggesting IDO involvement 
in the mechanism of action of in vitro generated MDSCs. Since IDO is not present 
among validated targets of STAT3, we are planning new experiments to test the 
effect of Stattic, the inhibitor of STAT3 phosphorylation, on the expression of 
IDO in MDSCs induced in vitro. 
 
Besides the characterization of the molecular mechanisms active in MDSCs, we 
also evaluated the fate of suppressed T cells and since the reduction in the T cell 
viability due to apoptosis was not enough to account by itself for the 
immunosuppression exerted by MDSCs, we searched for additional mechanisms 
of T cell impairment. We focused on T cell exhaustion, that was initially studied 
in chronical viral infections, in particular in LCMV 171, but that was reported to 
have a role also in promoting tumor escape. We evaluated the expression of PD-1 
and LAG-3 on suppressed T cells, two markers that have been related to T cell 
exhaustion and indeed we found the up-regulation of PD-1 on suppressed CD8+ T 
cells and the increase of LAG-3 expression both on CD4+ and CD8+ T 
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lymphocytes cultured with MDSCs. LAG-3 is a CD4 homologue expressed by 
many cells of the hematopoietic lineage, such as B, NK, γδ T cells, activated T 
cells, Tregs and TILs 188,189 and its expression negatively regulate proliferation, 
activation and homeostasis of T cells. LAG-3 is known to interact with MHC-II 
with high affinity and it was reported that blocking LAG-3/MHC-II interaction by 
the use of a mAb anti-LAG-3 increased the number of CD4+ and CD8+ T cells 
entering division, after stimulation with APCs and low antigen concentrations 190. 
Since our in vitro-derived MDSCs express MHC-II  and this molecule is further 
increased by the contact with activated T cells, we speculate that an interaction 
between HLA class II and LAG-3  could be a critical mechanism that mediate the 
induction of immunosuppression. This hypothesis is supported by a study 
performed in mouse models and demonstrating that CD4+ T cell tolerance 
depended on MHC-II expression. Interestingly, cell-to-cell contact between CD4+ 
T cells and MDSCs could enhance the immunosuppressive activity of MDSCs by 
cross-linking of MHC-II 191. Although the exact mechanism of MHC class II 
regulation in MDSC is not clear, STAT3 might play a role in this effect because 
several cytokines produced by the tumors trigger STAT3 signalling in myeloid 
cells and STAT3 up-regulation is a common finding in myeloid cells 109,192,193. 
We speculate that the negative effect of MHC-II/LAG-3 interaction on T cell 
functionality might be  enhanced by the binding of B7-H1, expressed on MDSCs, 
to its receptor PD-1, present on activated T lymphocytes. The synergistic effect of 
PD-1 and LAG-3 in promoting tumor immune escape was proved by a work 
analyzing CD8+ T cells specific for NY-ESO-1 (a “cancer-testis” antigen) present 
in peripheral blood or tumor site in patients with ovarian cancer. Interestingly, 
tumor-derived NY-ESO-1-specific CD8+ T cells demonstrated impaired effector 
function and enriched co-expression of LAG-3 and PD-1, as compared to 
peripheral blood CD8+ T lymphocytes. Expression of LAG-3 and PD-1 was up-
regulated by IL-10, IL-6 and tumor-derived APCs. Functional analysis revealed 
that CD8+/LAG-3+/PD-1+ T cells were more impaired in IFN-γ and TNF-α 
production as compared to LAG-3+/PD-1- or LAG-3-/PD-1- CD8+ T cells 
(Matsuzaki et al). The synergistic effect of PD-1 and LAG-3 in the impairment of 
immune responses has been demonstrated also in Sa1N- and MC38-inoculated 
mice. In fact the treatment with the combinatorial anti-LAG-3/anti-PD-1 
immunotherapy demonstrated higher efficacy in tumor eradication and in the 
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enhancement of adaptive immune responses as compared to anti-LAG-3 and anti-
PD-1 monotherapy 194. 
Studies related to LAG-3 and PD-1 therefore support our hypothesis that these 
molecules could be involved in T cell functional impairment mediated by 
MDSCs, and that their overexpression could be related to IL-10 signalling. 
However, a very recent study challenged the specificity of these molecules as 
markers of T cell exhaustion 174. In fact, it was demonstrated that the expression 
of LAG-3, PD-1 and other inhibitory receptors changed in different subsets of 
CD8+ T cells, on the basis of the degree of differentiation, and that the expression 
of multiple inhibitory receptors positively correlated to T cell activation 174. To 
understand if MDSC-induced LAG-3 and PD-1 expression in activated T cells are 
really associated to T cell exhaustion, we are planning to perform a gene 
expression analysis on suppressed T cells to evaluate if they present a gene 
expression profile of exhausted T cells.  
 
In conclusion, we demonstrated that IL-10 signalling through STAT3 leads to the 
expression on MDSCs of B7-H1 that, in turn, can interact with its receptor PD-1 
on T cells. PD-1/B7-H1 and LAG-3/HLA class II interactions probably mediate  
T cell function impairment. All these results were obtained using an in vitro 
model of MDSC generation, however we are investigating if the same 
mechanisms are active also in vivo in cancer patients. To this aim, we analyzed 
both myeloid and lymphoid cells present in liver metastases of colorectal cancer 
patients. We identified B7-H1 expression on a small subset of cells that had the 
same phenotype of MDSCs 67. However, to characterize these cells as MDSCs, 
we need to perform a functional assay to determine if this population of cells is 
endowed with suppressive activity and to test if B7-H1 plays a role in 
immunosuppression. By analysing CD4+ and CD8+ T cells present in liver 
metastases, we observed that PD-1 was expressed on both cell subsets, thus 
supporting the hypothesis of a possible interaction between B7-H1 and its 
receptor PD-1, while we did not observe LAG-3 expression on T cells. Since it 
was demonstrated that the expression of inhibitory receptors was dependent on the 
differentiation and activation state of T cells 174, the absence of LAG-3 could be 
due to the fact that lymphocytes in the tumor microenvironment have a different 
phenotype and degree of activation compared to the in vitro conditions. Therefore, 
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further studies are needed to elucidate the mechanisms underlying 
immunosuppression at the tumor site.                                          
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PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
A human promyelocytic-like population is responsible for the immune
suppression mediated by myeloid-derived suppressor cells
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We recently demonstrated that human
BM cells can be treated in vitro with
defined growth factors to induce the rapid
generation of myeloid-derived suppres-
sor cells (MDSCs), hereafter defined as
BM-MDSCs. Indeed, combination of
G-CSF  GM-CSF led to the development
of a heterogeneous mixture of immature
myeloid cells ranging from myeloblasts
to band cells that were able to suppress
alloantigen- and mitogen-stimulated
T lymphocytes. Here, we further investi-
gate the mechanism of suppression and
define the cell subset that is fully respon-
sible for BM-MDSC–mediated immune
suppression. This population, which dis-
plays the structure and markers of promy-
elocytes, is however distinct from physi-
ologic promyelocytes that, instead, are
devoid of immuosuppressive function. In
addition, we demonstrate that promyelo-
cyte-like cells proliferate in the presence
of activated lymphocytes and that, when
these cells exert suppressive activity, they
do not differentiate but rather maintain
their immature phenotype. Finally, we
show that promyelocyte-like BM-MDSCs
are equivalent to MDSCs present in the
blood of patients with breast cancer and
patients with colorectal cancer and that
increased circulating levels of these
immunosuppressive myeloid cells corre-
late with worse prognosis and radio-
graphic progression. (Blood. 2011;118(8):
2254-2265)
Introduction
One of the mechanisms of immune tolerance induced by cancer is
based on the expansion of myeloid-derived suppressor cells
(MDSCs), a heterogeneous population of immature myeloid cells,
which accumulate in the blood, lymph nodes, BM, and tumor sites
in patients and experimental animals with neoplasia, capable of
inhibiting both adaptive and innate immunities.1,2 The heterogene-
ity of MDSCs has always been a hallmark of this cell population
since its original description, and many studies advanced that
MDSCs might be composed of cells at several stages of
differentiation of the myeloid lineage (Lin) sharing the same
functional properties.2 To explain this heterogeneity, it was
advanced that the patterns of cytokines/chemokines that arm
myeloid cells with inhibitory function may be tumor dependent.
For all these reasons, MDSCs have been shown to express different
surface markers, depending both on the stage of myeloid develop-
ment examined and the differentiation context provided by factors
secreted by cancer cells.
In this respect, we recently demonstrated that the cytokines
GM-CSF, G-CSF, and IL-6 allowed a rapid generation of MDSCs
from precursors present in human BM and that the immunoregula-
tory activity of BM-derived MDSCs (BM-MDSCs) depended on
the C/EBP transcription factor.3
In the present study, we further characterized BM-MDSC
mediated-immune suppression. Analogously to tumor-induced MD-
SCs, BM-MDSCs consist of a heterogeneous population of imma-
ture myeloid cells. We thus investigated whether the immune
regulatory function of BM-MDSCs could be attributed to different
myeloid subsets induced by cytokine treatment or rather to a
specific subpopulation. Our results indicate that only one immature
cell population, with structure and phenotype resembling promyelo-
cytes, is responsible for the whole immune suppression mediated
by BM-MDSCs and that a cell population with a similar phenotype
is expanded in patients with breast cancer and patients with
colorectal cancer.
Methods
BM samples, human cohorts, and treatments
Fresh BM aspirate samples with normal cytologic characteristics were
obtained from patients enrolled in the protocol AIEOP-BFM-ALL 2000,
with suspected leukemia or lymphomas, patients with lymphatic leukemia
after 78 days without recurrences, and patients with lymphatic leukemia
after BM transplantation as a part of the diagnostic follow-up. Informed
consent was obtained from all participating persons, in compliance with the
Declaration of Helsinki, before the study that was approved by the ethics
committee of the Azienda Ospedaliera of Padova. For more details, see
supplemental Methods (available on the Blood Web site; see the Supplemen-
tal Materials link at the top of the online article).
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BM aspirates were subjected to lysis to remove red blood cells, with a
hypotonic solution of ammonium chloride. Cells were plated (2  106 cells/
well) into a 24-well tissue culture plate (Becton Dickinson) in IMDM
(Gibco Invitrogen) supplemented with 10% FBS (Gibco), 0.01M HEPES,
penicillin/streptomycin, and -mercaptoethanol. Cells were cultured with
40 ng/mL G-CSF and GM-CSF for 4 days at 37°C, 8% CO2. Human
recombinant GM-CSF was a gift from J. F. Parkinson (Bayer Healthcare
Pharmaceuticals), human recombinant G-CSF was purchased from Sanofi
Aventis.
Patients with solid tumors
Peripheral blood specimens were collected from patients with stage IV
colorectal cancer (n  25) at the University of Miami Sylvester Comprehen-
sive Cancer Center (UMSCCC) and stage IV breast cancer (n  25) at
UMSCCC and at the Medical University of South Carolina Hollings Cancer
Center starting a new line of therapy. Venous blood was collected in K2
EDTA lavender-topped tubes (BD) before initiation of therapy, after every
other cycle of therapy, and at the time of progression. Protocol Review
Committees at Hollings Cancer Center and UMSCCC and Institutional
Review Boards at both institutions approved this study. Written consent was
obtained from all subjects.
Patients with solid tumors: statistical
Random effects linear regression was used to model the association
between MDSCs and time in responders and nonresponders. The outcome
was log (MDSCs), and predictors were time, response status, and an
interaction between time and response. Random intercepts were included to
account for correlation of repeated measures of MDSCs over time from the
same patients. The coefficient on the interaction term was tested to
determine whether the change in MDSCs over time was the same compared
with difference in responders and nonresponders whereby an  level of 0.05
was used. Results were displayed graphically whereby each patient’s
MDSC responses are shown over time, with the estimated regression model
shown as solid straight lines. Standard model diagnostics were used to
ensure that assumptions about residuals were met. Kaplan-Meier analysis
was used to estimate survival distributions, and differences in survival were
tested with log-rank tests. Linear regression was used to determine
association between circulating tumor cells (CTCs), Swenerton score (SS),
and MDSCs, including estimation of slope, correlation coefficient, and
statistical significance of the association. Overall survival (OS) was defined
as time of study enrollment to date of death.
Flow cytometric analysis, Abs, and reagents
Cells were harvested and incubated with FcReceptor (FcR) Blocking
Reagent (Miltenyi Biotec) to saturate FcR and then labeled with monoclo-
nal Abs. For a detailed description of the Abs and of the methods used for
labeling, see supplemental Methods. Data acquisition was performed with
FACSCalibur or LSRII flow cytometer (Becton Dickinson), and data were
analyzed with FlowJo software (TreeStar Inc).
Cytospin preparation
Cytospins were obtained by centrifuging 1104 cells on microscope slides
and stained with May-Gru¨nwald-Giemsa dye (Bio-Optica) for 5 and
15 minutes, respectively. Cell morphology was examined by microscopic
evaluation of stained cells using a Leica DM 2000 microscope (Leica
Microsystems) with Leica lenses at 40 magnification and without
immersion oil. Pictures were taken using a Leica DFC 295 camera (Vashaw
Scientific Inc), acquired with Leica Acquisition Suite Version 3.5 (Meyer
Instruments) and processed with Adobe Photoshop CSI (Adobe Systems).
Confocal microscopic analysis
Cells were fixed with 4% paraformaldehyde on polylysinated 14-mm round
Menzel-Glaser glass in the dark for 15 minutes at room temperature and
permeabilized for 5 minutes with 0.1% Triton X-100 (Sigma-Aldrich) in
PBS, pH 7.4, before incubation for 1 hour at room temperature with PBS
2% BSA (Sigma-Aldrich) and 5% normal goat serum (Sigma-Aldrich).
Cells were stained with mAb diluted in PBS 0.5% Tween for 1 hour at room
temperature in the dark. Slides were then washed with the same buffer and
incubated with the secondary Abs for 1 hour at room temperature in the
dark. For a detailed description of the Abs and of the methods used for
confocal microscopy, see supplemental Methods.
Separation of BM-MDSC subsets
Lin and Lin fractions were separated from BM-MDSCs with Lineage
Cell Depletion Kit (Miltenyi Biotec), a magnetic labeling system for the
depletion of mature hematopoietic cells, following the manufacturer’s
instructions.
Myeloid fractions were also separated through cell sorting. Briefly,
single-cell suspensions of ex vivo BM or BM-MDSCs were stained with
anti-CD11b–PE, anti-CD16–FITC, and anti-CD3–PC7 and sorted on a
MoFlo (DakoCytomation). CD11blow//CD16 cells, CD11b/CD16 cells,
and CD11b/CD16 cells were isolated, excluding lymphocytes, on the
basis of CD3 expression and forward/side scatter parameters. All the
fractions were obtained with a purity of  90%. Alternatively, myeloid
populations were isolated through 2 consecutive magnetic sortings; in the
first round, BM-MDSCs were depleted of CD3/CD19/CD56 lympho-
cytes, with a cocktail of immunomagnetic beads obtained by combining
anti–human CD3, CD19, and CD56 beads (Miltenyi Biotec). Subse-
quently, the CD3/CD19/CD56 fraction was depleted of CD11b cells
with immunomagnetic anti–human CD11b beads (Miltenyi Biotec).
CFSE or CellTrace labeling and proliferation assay
PBMCs were isolated from the peripheral blood of healthy donors by
density centrifugation as described.4 Cell purity was checked by FACS
analysis on forward/side scatter parameters, and viability was checked by
Trypan blue dye exclusion.
PBMCs were stained with CFSE (Invitrogen Molecular Probe; range,
2-4M) or with 2M CellTrace Violet Cell Proliferation Kit (Invitrogen
Molecular Probe), according to the manufacturer’s instructions. For a
detailed description of the methods of the labeling and proliferation assay,
see supplemental Methods.
Isolation of human monocytes and granulocytes
Human granulocytes and PBMCs used for confocal microscopic analysis
were obtained from peripheral blood of healthy donors, as described,4
whereas human monocytes were prepared from PBMCs by short-term
adherence to plastic. Briefly, PBMCs were isolated from leukocyte-
enriched buffy coats (Transfusion Center) and incubated for 1 hour at 37°C
and 5% CO2 in flasks (Becton Dickinson) with the use of RPMI 1640
medium (Life Technologies) supplemented with 3% human serum. Nonad-
herent cells were removed by washing gently the flask with RPMI 1640
medium, and adherent monocytes were removed for successive analysis.
Statistical analysis
The statistical significance to compare parametric groups was determined
by the Student t test, whereas the Mann-Whitney U test was used to
compare nonparametric groups. Values were considered statistically signifi-
cant with P 	 .05. Absence of significance was not reported for brevity.
Results
BM-MDSCs down-regulate the CD3 chain expression in CD8
T cells and require a cell-to-cell contact to inhibit
alloantigen-activated T lymphocytes
BM-MDSCs consist of a heterogeneous combination of immature
myeloid cells that, based on the combined staining with anti-
CD11b and anti-CD16 Abs, can be qualified as differentiating cells
that range from myeloblasts to band cells, albeit with variable
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proportions in different cultures.3 We initially addressed whether
some of MDSC functional properties, described both in mice and
patients with cancer, were also shared by BM-MDSCs. In this
regard, one of the mechanisms proposed to explain T-cell dysfunc-
tion induced by MDSCs is the proliferative arrest of Ag-activated
T cells caused by loss of CD3
 chain expression,5 a proximal
TCR-associated signaling molecule necessary for correct assembly
and function of the TCR itself.
To understand whether BM-MDSC–mediated immune suppres-
sion induced a decrease in CD3
 expression, we set up allogeneic
MLRs, with CFSE-labeled PBMCs that were stimulated with a
pool of -irradiated allogeneic PBMCs and cocultured with
-irradiated BM-MDSCs. After 7 days, cell cultures were har-
vested, and CD3
 chain expression was determined by intracellular
staining after gating on CFSECD8CD3 cells. As shown in the
representative experiment of Figure 1A, BM-MDSCs induced a
marked decrease in T-lymphocyte proliferation, and this effect was
accompanied by a significant reduction in the intracellular levels of
CD3
 chain in CD8 T cells cocultured with BM-MDSCs (Figure
1B); this result was also confirmed by gating on CFSECD8
T cells (data not shown). Moreover the reduction of CD3
 chain
expression was also accompanied by a decrease in the surface
expression of CD3 chain (supplemental Figure 1A), implying that
both chains might be the target of BM-MDSC activity; however,
down-regulation of CD3 chain expression was less evident in
comparison to CD3
 chain.
Several studies have shown that MDSCs inhibit immune
responses through cell-to-cell contact;6,7 to address this point, we
set up cultures with CFSE-labeled PBMCs, which were stimulated
with anti-CD3/CD28 and coincubated with BM-MDSCs, either in
the presence or absence of a transwell. The insert ensures the flow
of metabolites between the 2 chambers, so that if the immune
suppression of BM-MDSCs depends exclusively on the release of
soluble molecules, the separation would not prevent the suppres-
sive program of BM-MDSCs. As assessed by the reduction of the
CFSE dilutions in PBMCs stimulated in the presence of BM-
MDSCs compared with the control cultures without BM-MDSCs,
an inhibitory effect was evident only in the presence of a
cell-to-cell contact between lymphocytes and BM-MDSCs, be-
cause separation of BM-MDSCs by the insert did not affect T-cell
proliferation (Figure 1C).
We also performed allogeneic MLRs in which the levels of
suppression were evaluated through 3HTdR incorporation. MLRs
were set up with different combinations of responder and stimula-
tor PBMCs. In these experiments the proliferative rate of responder
PBMCs varied, most probably as a result of the different HLA
mismatches between effectors and stimulators, which influenced
the magnitude of allogeneic response. Interestingly, we observed
that in the presence of a high proliferation rate of responder
PBMCs ( 30  103 cpm), BM-MDSCs could exert a signifi-
cantly higher suppression of the proliferation, in comparison to a
lower proliferation rate of responder lymphocytes (Figure 1D).
Indeed, when we evaluated the ability of BM-MDSCs to suppress
CD3/CD28-mediated T-lymphocyte activation, that is, a condition
in which T lymphocytes are massively activated, suppression was
achieved in  90% of the cases, that is, in a higher proportion of
cases compared with alloantigen-specific MLRs (data not shown).
These results suggest that MDSCs become fully competent in their
suppressive function only in the presence of strongly activated
T lymphocytes.
Lin fraction of BM-MDSCs is responsible for the immune
suppressive activity
As described earlier, the gradual increase of CD11b and CD16
expression is used to distinguish among all the differentiation
stages of myeloid commitment. CD16 is considered a marker for
mature myeloid cells; thus, the CD11b/CD16 cell subset repre-
sents a more immature myeloid population than the CD11b/
Figure 1. Characterization of BM-MDSC–mediated immune suppression. (A) CFSE-labeled PBMCs were stimulated with allogeneic -irradiated PBMCs without (left) or
with (right) -irradiated BM-MDSCs added at a ratio of 1:1. After 7 days, cell cultures were harvested, labeled with anti-CD3, and analyzed in the CD3/CFSE cell gate. The
figure shows a representative experiment of cell division analysis of 3 performed. The percentages of the undivided cells are indicated. (B) After 7 days of culture, cultures set
up as in panel A were labeled with anti-CD3, anti-CD8, fixed, and then labeled with anti-CD3
. Mean fluorescence intensity (MFI) of CD3
 was calculated in the
CFSE/CD3/CD8 cell gate. On the left panel, black histogram represents the MFI of stimulated PBMCs without BM-MDSCs, whereas the white histogram refers to MFI of
stimulated PBMCs in presence of -irradiated BM-MDSCs. On the right panel, MFI values of CD3
 are presented as mean  SE of 3 independent experiments; P  .034,
Student t test. (C) PBMCs were labeled with CFSE and stimulated with coated anti-CD3 and soluble anti-CD28 (left) and cocultured with BM-MDSCs in the presence (right) or
in the absence (center) of a transwell. After 4 days, cells were harvested, labeled with anti-CD3, and analyzed in the CD3/CFSE gate. The figure shows a representative
experiment of 3. The percentages of the undivided cells are indicated. (D) Proliferation of alloactivated PBMCs cocultured either with or without -irradiated BM-MDSCs was
assessed by 3H-thymidine incorporation. White dots represent the proliferation of stimulated PBMCs without BM-MDSCs, and gray dots correspond to the proliferation of
alloactivated PBMCs in presence of BM-MDSCs. Twenty independent experiments are shown with proliferation of alloactivated PBMCs 	 30  103 cpm (columns 1 and 2)
and 15 experiments with proliferation  30  103 cpm (columns 3 and 4). P  .01 and P 	 .001, Mann-Whitney U test.
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CD16 cell subset.8 We observed that the in vitro expansion of
BM-MDSCs with the combination of G-CSF GM-CSF gave rise
to a significant increase in immature CD11b/CD16 elements
(Figure 2A; P 	 .001 compared with untreated BM) and that the
presence of these cells was correlated with induction of suppressive
activity (data not shown).
Interestingly, other groups previously described in patients with
cancer an expansion of Lin population endowed with suppressive
activity.9 We thus decided to explore the function of more immature
subsets among BM-MDSCs after cell enrichment by immunomag-
netic sorting with a cocktail of Abs targeting Lin Ags, with the aim
to deplete mature myeloid populations and B, T, and natural killer
lymphocytes from BM-MDSC cultures. This negative-selection
procedure yields a population of cells enriched in hematopoietic
stem cells and very early myeloid progenitors that are CD11blow//
CD16 (Figure 2B). Although the cell purity is rather high in the
Lin fraction, the Lin fraction was heterogeneous and still
contained lymphocytes, mature, and immature myeloid cells. The
structure of the different populations was examined by May-
Gru¨nwald-Giemsa staining of cytospin cell preparations and con-
firmed that unsorted BM-MDSCs were composed of both mononu-
clear and polymorphonuclear cells, whereas the Lin fraction was
mainly composed of large mononuclear cells (Figure 2B).
To test the suppressive activity of BM-MDSC fractions we
measured the proliferation of T cells (allogeneic with respect to
BM-MDSCs) by CFSE dilution after CD3/CD28 stimulation in the
presence of unsorted, Lin, or Lin BM-MDSC cell subsets. In
cultures of T cells stimulated with anti-CD3/CD28, the addition of
whole BM-MDSCs caused both a moderate increase in undivided
T-cell fraction and a strong reduction in the numbers of CFSE
Figure 2. Lin subset contained within BM-MDSCs
shows potent suppressive activity. (A) Flow cytomet-
ric analysis of BM cells cultured for 4 days with G-CSF
 GM-CSF (BM-MDSCs) or without growth factors (NT
BM). At the end of the culture, cells were harvested and
labeled, and the percentages of CD11b/CD16 cells
were calculated. The figure represents 22 independent
experiments; P  .001, Student t test. (B) Flow cytomet-
ric profile of CD16 and CD11b expression and May-
Gru¨nwald-Giemsa staining on BM-MDSCs before and
after immunomagnetic depletion with Lin Ab cocktail.
(C) Flow cytometric analysis of the proliferation of
allogenic PBMCs, stained with CFSE and activated with
anti-CD3 and anti-CD28 for 4 days, in the presence of
either BM-MDSCs or the fractions Lin or Lin sorted
from BM-MDSCs. The figure, in which the percentages
of undivided CD3/CFSE lymphocytes are shown,
represents 1 of 3 independent experiments. (D) Number
of CD3/CFSE events obtained after activation of
PBMCs with anti-CD3/CD28 and cocultured in the
presence of BM-MDSCs or the subsets Lin and Lin
sorted from BM-MDSCs. The figure, in which the black
bars refer to undivided cells and the gray bars to divided
cells, represent the mean  SE of 6 independent experi-
ments. The values of P are indicated in the figure,
Mann-Whitney U test. (E-F) Evaluation of MFI of CD3
chain expression and percentage of the CD3/CFSE
cells in PBMCs stimulated with anti-CD3/CD28 in the
presence of BM-MDSCs or the Lin and Lin fractions.
Values are mean  SE of 6 independent experiments.
All comparisons among BM-MDSCs containing cultures
versus cultures without BM-MDSCs, P  .041 (E) and
P  .009 (F), respectively, Mann-Whitney U test.
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cells (Figure 2C-D). The Lin fraction was endowed with the
highest suppressive activity compared with both the unsorted
population and the Lin subset, which basically had the same
suppressive ability of the unsorted BM-MDSCs (Figure 2C-D).
We also observed that levels of CD3 chain expression in
activated T cells suppressed by the Lin subset of BM-MDSCs
were constantly reduced in terms of MFI (Figure 2E) in all the
experiments performed. This decrease in CD3 expression was also
accompanied by a significant reduction in the percentage of
CD3/CFSE cells (Figure 2F), therefore suggesting that suppres-
sion by the Lin subset of myeloid cells was mediated through a
profound alteration of signaling machinery associated with a
significant reduction in the numbers of CD3 T lymphocytes.
Suppressive activity of BM-MDSCs is entirely contained within
the CD11blow//CD16 cell subset
Experiments performed with the Lin subset of BM-MDSCs
highlighted that cells with the strongest suppressive activity were
present in this fraction, supporting data from other laboratories
showing that MDSCs obtained from patients with cancer can be
traced among Lin cells.9 However, this separation protocol does
not allow to distinguish various differentiation stages during
myeloid commitment. Therefore, to find out whether suppressive
activity of BM-MDSCs was either shared by a number of immature
subsets or limited to a specific differentiation stage, we separated
defined myeloid subsets through cell sorting.
We sorted 3 different myeloid fractions from fresh BM and
cultured BM-MDSCs, based on the expression levels of CD11b and
CD16 Ags: the low/negative fraction CD11blow//CD16, the
intermediate subset CD11b/CD16, and the double-positive frac-
tion CD11b/CD16, as shown in Figure 3. Because BM-MDSCs
do not contain mature granulocytes (CD11b/CD16high), which are
instead present in BM cells, we excluded from the analysis the
mature granulocyte population (Figure 3A-B).
May-Gru¨nwald-Giemsa staining showed that both unsorted
fresh BM cells and cultured BM-MDSCs had an heterogeneous
Figure 3. CD11blow//CD16 phenotype defines the subset responsible for the immune suppression in BM-MDSCs. (A) Flow cytometric evaluation of CD11b and CD16
markers in BM-MDSC or sorted CD11blow//CD16, CD11b/CD16 and CD11b/CD16 cell populations from fresh BM samples (left), structural analysis by
May-Gru¨nwald-Giemsa staining (center), and CFSE dilution proliferation assay (right) in which values reported on histograms represent the percentages of cells in the parental,
undivided generation. (B) Flow cytometric evaluation of CD11b and CD16 markers in BM-MDSCs or sorted CD11blow//CD16, CD11b/CD16, and CD11b/CD16 cell
populations from BM-MDSCs (left), structural analysis by May-Gru¨nwald-Giemsa staining (center), and CFSE dilution proliferation assay (right) in which values reported on
histograms represent the percentages of cells in the parental, undivided generation. (C) Suppression of allogenic CFSE PBMCs activated with anti-CD3 and anti-CD28 and
cocultured in the presence of 1:1 ratio of the different populations sorted from human BM-MDSCs. The suppression was calculated, analyzing the number of proliferating cells
from generation 3 to generation 10, assumed to be 100% without BM-MDSCs. Mean  SE of 3 independent experiments. P  .01, Student t test, all comparisons among
BM-MDSCs containing cultures versus cultures without BM-MDSCs.
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structure, as confirmed by other phenotypical features; moreover,
in our cell cultures we never found contaminating CD14/CD15
macrophages that could contribute to suppressive activity of
BM-MDSCs (data not shown). The CD11blow//CD16 subset
isolated from fresh BM cells comprised cell elements with the
appearance of myeloid progenitors and promyelocytes, whereas the
corresponding subset isolated from BM-MDSCs contained baso-
philic cells, resembling promyelocytes (Figure 3A-B). The CD11b/
CD16 subset separated from fresh BM contained myelocytes,
metamyelocytes, eosinophils, and monocytes, whereas BM-
MDSCs included mainly cells resembling monocytes and eosino-
phils. At last, metamyelocytes and band cells were present among
CD11b/CD16 cells isolated from both populations.
When we tested the potential suppressive activity of the sorted
subsets, only the CD11blow//CD16 cell population isolated from
BM-MDSCs was able to suppress the proliferation of activated T cells,
whereas the CD11b/CD16 and CD11b/CD16 cell subsets purified
from BM-MDSCs were completely devoid of suppressive activity
(Figure 3C). Cumulative data reported in Figure 3C show that the entire
suppressive activity of BM-MDSCs is contained within a single
subset of cytokine-conditioned promyelocytes, which were able
not only to block lymphocyte proliferation but also to affect IFN-
production and to induce T-cell apoptosis (data not shown). None
of the 3 corresponding subsets isolated from fresh BM cells was
able to interfere with T-lymphocyte proliferation (Figure 3A),
further highlighting that priming of BM cells with cytokines is
mandatory to induce immunoregulatory MDSCs.
Cytokine-stimulated CD11blow//CD16 cell subset consists of
immature and large mononuclear myeloid cells
The phenotype of the suppressive CD11blow//CD16 cell subset
was further analyzed by flow cytometry. In the course of our
attempt to increase the purity and to minimize the manipulation of
sorted cells, we observed that the suppressive CD11blow//CD16
subset could be also separated through a progressive sorting with
magnetic beads in which BM-MDSCs were first depleted of CD3,
CD19, and CD56 cells, and the resulting population was then
depleted of CD11b cells. The remaining, negatively selected cell
population (CD11blow/ BM-MDSCs) had the same phenotypic and
suppressive characteristics of the sorted CD11blow//CD16 BM-
MDSCs (supplemental Figure 1B).
CD11blow//CD16 cells sorted from fresh BM had a peculiar
structure, characterized by a high side scatter, occupying the region
of normal granulocytes, but, after 4 days of culture with G-CSF 
GM-CSF, these cells gradually reduced their side scatter and
increased the forward scatter, thus moving to the monocyte region
(supplemental Figure 1C; Figure 4). However, the surface pheno-
type of the suppressive CD11blow//CD16 cells, separated from
BM-MDSCs, indicated that this population lacked the expression
of the monocytic marker CD14 and was positive for the CD15
granulocytic Ag (Figure 4A), thus implying that it had characteris-
tics distinct from both mature monocytes and granulocytes.
The suppressive subset was negative for the lineage markers
and expressed the myeloid markers CD13 and CD33; IL4R chain
was expressed at low intensity, as previously shown.4,10 The
expression of CD66b was down-regulated in the cytokine-treated
subset, compared with the same population sorted from fresh BM
cells, whereas CD117 increased its expression after induction with
G-CSF  GM-CSF (Figure 4A; supplemental Figure 1C). Two
discrete populations with different expression of HLA-DR mole-
cule (low or negative) were noted. The suppressive cells expressed
CD39 but lacked CD73, which are both expressed on the surface of
human T-regulatory lymphocytes.11 Finally, this subset did not
express B7-H1 and slightly expressed B7-H2 and B7-H3 (Figure
4A), members of B7 family that are able to regulate immune
responses and to induce immunologic tolerance.12
We also estimated the proliferative rate of the CD11blow//
CD16 cells by intracellular staining of Ki-67 cells and observed
that 97% of the cells expressed this Ag, indicating that these cells
were actively proliferating in response to cytokine treatment
(Figure 4A).
It is known that during the differentiation of polymorphonuclear
leukocytes, myeloblasts and promyelocytes proliferate and gener-
ate primary granules,13 and one of the proteins contained in these
granules is the enzyme myeloperoxidase (MPO). CD11blow//
CD16 cells isolated from BM-MDSCs induced from different
human samples could assume either 1 of 2 main structural patterns:
cells with large nuclei and reduced cytoplasm without granules and
cells with more abundant cytoplasm and a discrete number of
cytoplasmic granules (Figure 4B). By confocal microscopy, the
MPO protein appeared prevalently located, as expected, within
granules; however, the cytoplasm of the agranular cells showed a
diffuse pattern of expression (Figure 4B). Classic, mature granulo-
cytes presented the typical polylobated nucleus surrounded by
azurophilic granules containing MPO, whereas the MPO expres-
sion in monocytes seemed to be confined within the lysosomal
compartment (Figure 4B), as described.14
We also used a novel monoclonal Ab against human arginase
1 (ARG1) to evaluate whether the enzyme was present in CD11blow//
CD16 cells and whether it was coexpressed with MPO, as
suggested by some studies.15 The analysis of ARG1 in this
suppressive subset showed cells with different expression pattern:
in most cells this enzyme was partially colocalized with MPO, but
some cells stained negative for ARG1 (Figure 4B). In contrast,
mature granulocytes showed a complete colocalization of the
2 enzymes, whereas monocytes did not express ARG1, as already
described.15 The CD11blow//CD16 cells isolated from fresh BM
cells stained positive for ARG1 but showed a decrease of MPO
expression, compared with the same population separated from
BM-MDSCs (Figure 4C). In comparison, freshly isolated CD11b/
CD16 and CD11b/CD16 cells, which represent more advanced
maturation stages, presented a progressive increase in the signals
for both enzymes (Figure 4C).
Activated T lymphocytes sustain the proliferative rate of the
BM-MDSC CD11blow/ cells and block their differentiation
process
The activation level of T lymphocytes appears to be critical to drive
the suppressive activity of BM-MDSCs (Figure 1D). To investigate
the relationship between T-cell activation and MDSC suppression,
we set up experiments in which either resting or activated T cells,
labeled with CellTrace fluorescent stain, were cocultured with
BM-MDSC cell subsets, so that we could trace unambiguously the
myeloid and lymphoid cell populations in the coculture and
evaluate proliferation after 4 days. As expected, we observed a high
proliferation rate of activated T cells in the presence of CD11b
BM-MDSCs, evaluated in terms of CellTrace dilution and, instead,
a reduction in the proliferation of T cells cocultured with the
suppressive CD11blow/ BM-MDSC fraction (Figure 5A second
lane). We also assessed the cell proliferation of the myeloid cell
subsets in the cultures by analyzing Ki-67 expression on gated
CD3/CellTrace cells. Interestingly, although the CD11b cell
subset of BM-MDSCs did not proliferate in culture with either
activated or resting T cells (Figure 5A third lane), the suppressive
HUMAN PROMYELOCYTE-LIKE SUPPRESSOR CELLS 2259BLOOD, 25 AUGUST 2011  VOLUME 118, NUMBER 8
 For personal use only. at Padova Pinali on January 5, 2012. bloodjournal.hematologylibrary.orgFrom 
CD11blow/ cell subset maintained a discrete proliferative capacity
in the presence of resting T cells, which was even increased with
the presence of activated T cells (geometric mean fluorescent
intensity 14.5 vs 29.2, respectively), suggesting that T-cell activa-
tion supports the proliferation of suppressive cells.
To understand whether suppressive BM-MDSC CD11blow/
cells maintain their phenotype or rather differentiate to more
mature myeloid subsets when cocultured with activated T lym-
phocytes, we analyzed the expression of differentiation myeloid
markers after cell coculture. After 4 days of culture we observed
that, only in the presence of activated T cells, promyelocyte-like
cells maintained their level of immaturity, as shown by the
levels of expression in the markers CD11b and CD16; moreover,
whereas HLA-DR and CD34 were maintained or even in-
creased, CD66b, a marker of secondary granules, was down-
regulated in the presence of activated T cells (Figure 5B).
Control cultures of immature promelocyte-like cells in the
absence of lymphocytes showed a differentiation pattern similar
to myeloid cells cocultured with resting T cells (Figure 5B),
thus suggesting that only the presence of activated T cells is
able to block the default differentiation process of immature
promyelocyte-like cells.
Figure 4. Phenotypic evaluation of the immune-suppressive subset CD11blow//CD16 contained within BM-MDSCs. (A) Flow cytometric analysis of CD11blow//CD16
cells sorted from BM-MDSCs. The expression of putative MDSCs markers, markers of mature and immature myeloid cells, and markers associated with tolerance was
evaluated relative to isotype control (black histograms). In the figure is presented 1 representative of 2 independent experiments. (B) Confocal microscopic localization of MPO
and ARG1 in CD11blow//CD16 cells, freshly isolated neutrophils, and monocytes. Scale bars  12 m. (C) Localization of MPO and ARG1 in CD11blow//CD16,
CD11b/CD16, and CD11b/CD16 cells isolated from fresh BM samples determined by confocal microscopy. Scale bars  20 m.
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Taken together these data indicate that promyelocyte-like cells
proliferate, their functional activity is associated with a delay in the
differentiation pathway, and both proliferation and block in the
differentiation pathway account for their expansion and mainte-
nance of an immature phenotype.
Increased circulating MDSC levels correlate with progression
and worse clinical prognosis
The suppressive myeloid population of BM-MDSCs was mainly
Lin, CD11blow/, HLA-DRlow/, but positive for myeloid markers
Figure 5. T-lymphocyte activation is driving BM-MDSC proliferation and immune suppression. (A) CellTrace-labeled PBMCs were stimulated with anti-CD3/CD28 in the
presence of BM-MDSC CD11b and CD11blow/ cell subsets, added at a ratio of 1:1. After 3 days, cell cultures were harvested, labeled with anti-CD3, and analyzed in the
CD3/CellTrace gate (M) and in the CD3/CellTrace (T) cell gate. The numbers indicated in the top graphs refer to the percentage of cells gated on either T cells (T) or on
myeloid cells (M). The central histograms show the profile of CellTrace dilution of either resting or stimulated T cells (gate T) cocultured with BM-MDSCs CD11b and
CD11blow/ subsets. Black and gray curves refer to undivided and proliferating cells, respectively. The bottom histograms show Ki-67 expression in BM-MDSCs CD11b and
CD11blow/ subsets (gate M) cocultured with either resting or stimulated T cells. Black histograms indicate isotype control. The figure shows a representative experiment of
3 performed. (B) Flow cytometric evaluation of CD11b, CD16, HLA-DR, CD34, and CD66b markers in CD11blow/ cell subset sorted from BM-MDSCs either before or after the
coculture with resting or anti-CD3/anti-CD28–activated T cells. The expression of these markers was compared with the autofluorescence signal (black histograms). In the
figure, 1 representative of 3 independent experiments is presented.
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CD33 (Figure 4), a subset with phenotype similar to MDSCs
previously described in tumor-bearing patients.9,16 Indeed, in the
blood of patients with stage IV breast cancer we could clearly
identify a Lin, HLA-DR, CD33, CD11b MDSC population
resembling in vitro–generated BM-MDSCs (Figure 6A-B). We
previously showed that this cell subset correlated with clinical
tumor stage,16 but it is still unknown whether circulating Lin,
HLA-DR, CD33, CD11b cells also correlate with either
metastatic tumor burden or OS in patients with cancer. We thus
evaluated the relationship between MDSCs and CTCs measured by
the CellSearch assay, a strong, independent predictor of survival in
patients with advanced breast cancer.17,18 In a cohort of patients
with stage IV breast cancer (n  25) CTCs (CellSearch) and
MDSCs were analyzed simultaneously. A generalized estimating
equation regression model was created and fitted individually for
each predictor. A significant correlation was observed between
Figure 6. Increase in circulating MDSC levels over time in patients with advanced solid tumors is associated with decreased survival times and radiographic
disease progression. Gating strategy for BM-MDSCs (A) and whole-blood MDSCs (B) is shown on a representative flow cytometric plot. (C) Random effects regression
model and correlation between MDSCs and CTCs. Flow cytometric analysis was performed on peripheral whole blood in a separate cohort of patients with stage IV breast
cancer (n  25) before initiation of therapy and at defined intervals during therapy. Blood for CTC determination by the CellSearch was simultaneously drawn. A significant
correlation was found between circulating MDSC levels (%) and CTCs (P  .0001). (D) Survival analysis by circulating MDSC levels (%) at first blood draw in patients with
stage IV breast cancer starting a new line of systemic chemotherapy (n  26). Survival estimates by median percentage of MDSCs ( 3.17% and 3.17%) with the use of the
first MDSCs observation (P  .048). (E) Survival estimates by median percentage of MDSCs ( 3.04% and  3.04%) with the use of MDSCs levels drawn at the last visit
(P  .018). (F) Survival analysis by circulating MDSC levels at time of study enrollment in patients with stage IV colorectal cancer. Survival estimates by medial percentage of
MDSCs ( 2.54% and  2.54%). (G) Analysis of relationship between changes in circulating MDSC levels over time and best radiographic response in patients receiving
systemic chemotherapy (n  25). Plot of MDSCs over time by “best response” defined as patients who achieved complete (CR) or partial radiographic response (PR) while on
systemic therapy versus patients who did not. MDSCs were drawn prospectively after every other cycle of therapy. Over time circulating MDSCs were significantly higher in
nonresponders than in patients with CR or PR as best response (*P  .015 comparing slopes).
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circulating MDSCs and CTCs (P  .0001; Figure 6C). As ex-
pected, no significant correlation was observed between CTCs and
SS (P  .92); indeed, CTCs are not a measure of metastatic tumor
burden, and levels do not correlate with SS in patients with
advanced breast cancer.17-19 To ascertain whether high circulating
MDSC levels were associated with poorer prognosis, survival
estimates in the breast cancer dataset were calculated with MDSC
levels (%), drawn either before starting a new line of therapy or
levels at the last blood draw. Patients with circulating MD-
SCs  3.17% (median) at baseline had a poorer OS than patients
with circulating MDSCs 3.17%, with median OS times of
5.5 months (95% confidence interval [CI], 0.5-11.3 months) and
19.32 months (95% CI, 8.7 months to infinity), respectively
(P  .048; Figure 6D). Likewise, elevated MDSC levels at the last
visit were also associated with a significantly poorer OS (P  .018),
with median survival times of 3.8 months (95% CI, 0.5-
7.7 months) and 16.7 months (95% CI, 3.8 months to infinity),
respectively (Figure 6E).
We then moved to examine another group of patients with
cancer. In a cohort of patients with stage IV colorectal cancer
(n  25) we also found that baseline levels of MDSCs before
starting chemotherapy also correlated with poorer OS (Figure 6F).
Patients with circulating MDSC levels greater than the median
value (2.54%) had significantly shorter median OS times than
patients with levels below the median value (35.6 vs 14.3 months;
P  .025; Figure 6F). We next investigated whether levels of
circulating MDSCs over time in patients with advanced solid
tumors receiving systemic chemotherapy correlated with clinical
outcomes. MDSC levels in the same cohort of patients with stage
IV colorectal cancer were drawn every other chemotherapy cycle.
Patients underwent routine radiographic assessments as clinically
indicated, typically every 2-3 months. Over time MDSC levels
were significantly higher in patients who had radiographic evi-
dence of progressive disease than in levels in patients who achieved
either a CR or PR as their best radiographic response (P  .015;
Figure 6G). Taken together, these clinical data suggest, for the first
time, that circulating MDSC levels, phenotypically similar to those
described in human BM experiments, are clinically relevant and
appear to (1) increase over time in patients with progressive
disease, (2) correlate with an established prognostic marker (CTCs)
in advanced breast cancer, and (3) show that persistently high or
increasing levels after chemotherapy are associated with
poorer survival.
Discussion
The aim of our study was to dissect the differentiation stage of the
suppressive myeloid cells by taking advantage of the in vitro
generation of MDSCs from the BM precursor.3 The suppressive
activity is fully induced in BM-MDSCs only after direct contact
with activated T lymphocytes, indicating that suppressive cells are
primed by the activation status of target cells and by a cell
membrane signal, a result analogous to data obtained with mouse
MDSCs.10 Moreover, this result is in line with the consideration
that myeloid suppressors play a role in turning off potential harmful
immune responses carried out by activated T lymphocytes.1,20 Our
results extend this idea, leading us to hypothesize that the activity
of MDSCs is dictated by the activation level of the T lymphocytes.
In fact, suppressive cells are unable to harm resting lymphocytes,
and the direct contact between these 2 cells might ensure that the
signals delivered by MDSCs are confined only to target cells and
not to bystander cells.
It is known that anti-CD3– and anti-CD28–activated T cells
secrete GM-CSF and IL-6,21 cytokines that drive the BM-MDSC
development from BM; however, we observed that BM-MDSCs
also are able to produce in vitro IL-6 during the culture with growth
factors (data not shown). Moreover, it was recently shown that
T lymphocytes, on TCR activation, produce soluble factors that
enhance fibroblasts production of IL-6.22 An attractive hypothesis
is that activated T cells release cytokines that might sustain the
induction of the suppressive cells or maintain their tolerogenic
activity, an autoregulative loop that has already been shown in a
different system.10
Among different cytokine combinations, GM-CSF and IL-6
were the most effective in generating, from healthy donor PBMCs,
suppressive CD33 cells that inhibited the proliferation and IFN-
production by autologous human T cells after CD3/CD28 stimula-
tion.23 These cells were large mononuclear CD11b HLA-DRlow
CD66b cells with basophilic and granular cytoplasm. When
molecules and enzymes participating in inhibitory pathways were
evaluated by either quantitative RT-PCR or cytofluorometry, NOS2,
TGF, VEGF, and NOX2 were found to be up-regulated, whereas
no significant changes in comparison with the nonsuppressive,
normal CD33 cells were detected for B7-H1, B7-H2, and
B7-H4.23 It thus appears that cytokines might induce different cells
with immunoregulatory properties when acting on either BM or
blood-circulating precursors. Whether these cells represent stages
of the same differentiation process is an issue that requires further
investigation. It is clear, however, that MDSCs described in the
present study are different from either fully differentiated or
activated granulocytes and monocytes.
We observed that the reduction of lymphocyte proliferation
induced by BM-MDSCs is accompanied by a decreased expression
not only of the CD3
 but also of the CD3 chain and by a reduction
in absolute numbers of T lymphocytes. It is known that the absence
or reduction of CD3
 chain impairs T-cell signaling and contributes
to immune cell dysfunction and evidence is accumulating that
expression of the CD3
 chain is markedly decreased in both
peripheral blood and tumor-infiltrating lymphocytes in patients
with different types of tumors.24,25 Significantly less is known
about the importance of the  chain of the CD3/TCR complex in
tumor immunity, even if some reports have shown down-regulation
of CD3 chain in patients with lung cancer and SCID.26-28
In this study we addressed the extent and relevance of cell
heterogeneity of MDSCs, generally accepted as a common feature
of this cell population, with the aim to define whether immunoregu-
latory properties of human BM-MDSCs can be attributed to  1
cell subsets. We observed that the treatment of BM cells with
G-CSF  GM-CSF resulted in a significant accumulation of
immature myeloid cells (Figure 2A).3 In this regard, we observed
that one of the differences existing between untreated BM and
BM-MDSCs was represented by the expansion of immature
myeloid cells expressing low levels of CD11b and negative for
CD16, a phenotype that is typically associated with myeloblasts
and promyelocytes, but not with more differentiated cells (Figure
2A and3). The accumulation of immature CD11b/CD16 cells in
BM-MDSCs led us to test the hypothesis that this myeloid
population was entirely responsible for the suppression exerted by
BM-MDSCs. Our results clearly indicate that the only subset
responsible for the immune suppression exerted by BM-MDSCs is
contained within the CD11blow//CD16 cell population of BM-
MDSCs, and other immature but more differentiated subsets, such
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as CD11b/CD16 and CD11b/CD16 cells, are completely
devoid of suppressive activity; accordingly, this subset was able to
proliferate in the presence of activated T cells, a feature that is lost
by more mature subsets. Interestingly, we also observed that
BM-MDSC CD11blow/ were able to exert suppressive activity
both on CD4 and CD8 subsets and to induce apoptosis of T cells,
an event that was marginal in T cells activated without BM-MDSC
CD11blow/ (data not shown).
Remarkably, the suppressive cell subset had a phenotype
corresponding to promyelocytes, and, indeed, these cells structur-
ally resembled promyelocytes, with a large regular, symmetric
nucleus, high nucleus/cytoplasm ratio, and basophilic cyto-
plasm. We sorted the corresponding subset from fresh BM
(CD11blow//CD16), containing mainly promyelocytes. The
2 subsets were indistinguishable from a structural point of view,
but they differed completely in terms of ability to suppress
activated T lymphocytes, because normal promyelocytes were
unable to exert any inhibitory activity (Figure 3A). Here, for the
first time, we show that MDSCs proliferate, that this activity is
linked to a block in the differentiation pathway, and, interest-
ingly, that both suppression and maturation depend on the
activation status of the T lymphocytes (Figure 5).
Because suppressive activity of myeloid cells is limited to a
specific subset of promyelocytic-like cells, and the more differenti-
ated populations are completely devoid of regulatory activity, this
implies that suppressive activity is not a stable trait of MDSCs but
rather a transitory state, possibly ending or being sustained
according to local signals coming from the microenvironment
where the immature cells migrate. These results, therefore, suggest
that MDSCs maintain a plasticity that enables them to differentiate
and suspend their tolerogenic program.
We found that ARG1 was expressed in the suppressive
CD11blow//CD16 cell subset and partially colocalized with
MPO, suggesting its main distribution within primary granules, as
suggested by Munder et al.15 However, in comparison with the
same population isolated from fresh BM, this subset had an
increased expression of MPO, which presented both an expected
granular and an uncommon agranular localization. We are currently
evaluating whether the altered expression of these enzymes is only
a marker of these cells or whether it is related also to their
suppressive function.
Finally, one of the challenges in studying MDSCs in humans
has been that the phenotype is not as well defined as in mice. We
show that MDSCs, defined as Lin, HLA DR, CD33, CD11b,
can be easily traced among blood circulating cells in patients with
advanced breast and patients with colorectal cancer, with levels
correlating with clinical outcomes.
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